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ABSTRACT 
This study explores the biological role of receptor-bound uPA 
in the process of human colon cancer invasion and metastasis an.d 
the therapeutic potential of uPA inhibitors in their prevention. 
An indirect receptor-bound uPA activity assay was developed 
to compare the potential of cultured cancer cells to generate 
plasmin on their surface in the presence of plasminogen. It was 
found that the total endogenous receptor-bound uPA activity on the 
surfaces of colon cancer cells correlated well with uPA-binding 
capacity expressed on their surfaces. These studies indicated the 
important role of uPAR in determining the levels of receptor-bound 
uPA activity on cultured colon cancer cells. This conclusion was 
confirmed by inhibiting uPAR gene expression in HCT116 cells 
using an antisense RNA strategy. The reduction of uPAR binding 
capacity on uPAR-antisense-transfected cells was associated with 
a marked decrease in the endogenous receptor-bound uP A activity. 
It was confirmed in this study that receptor-bound uPA is the 
main initiator of plasminogen-dependent ECM degradation by 
cultured colon cancer cells. The ability of colon cancer cells to 
initiate plasminogen-dependent ECM degradation correlated with 
the receptor-bound uPA activity on their surfaces. ECM degradation 
was reduced when colon cancer cells were transfected with a uPAR 
eDNA fragment in an antisense orientation which prevented normal 
translation of uPAR sense mRNA. 
A good correlation between metastatic potential and 
endogenous receptor-bound uPA activity was found when the 
"intracaecal" and "intravenous", but not the "intrasplenic" routes 
were used for introducing human colon cancer cells into 
immunodeficient (Nu/Nu) mice. The potential of HCT116 cells to 
form pulmonary tumours in nude mice after intravenous injection 
was diminished when the number of uPAR was reduced in the uPAR 
antisense-transfected HCT 116 cells. 
The effects of uPA inhibitors on colon cancer cell surface uPA 
activity, on the plasminogen-dependent ECM degradation by colon 
cancer cells and on the formation of experimental metastases were 
examined in this study. Compared to chemical inhibitors, higher 
concentrations of PAI-2 were required to inhibit receptor-bound 
uPA activity (ISO = 22.7 nM) than soluble uPA. The plasminogen-
dependent ECM degradation by HCT116 cells was inhibited by uPA 
inhibitors (I so% was 6611 M for PAI-2, 12~M for GGA-CMK and 
0.23mM for amiloride). Despite this, administration of amiloride in 
drinking water reduced pulmonary tumour formation in nude mic.e 
after intravenous injection of HCT116 cells. Conversely, 
administration of amiloride, GGA-CMK and TrasyloiR had no effect 
on hepatic tumour formation when HCT116 or KM12SM cells were 
introduced into nude mice intrasplenically. 
These results indicate that receptor-bound uPA is an essential 
element of colon cancer invasion. It initiates plasminogen-
dependent pericellular proteolysis thereby permitting cancer cells 
to penetrate the surrounding normal tissues including blood and 
lymphatic vessels. Therefore, natural uPA inhibitors such as PAI-2 
may have therapeutic potential in the prevention or treatment of 
local colon cancer invasion. In the process of colon cancer 
metastasis, receptor-bound uPA may also play an important role in 
early steps such as local invasion and intravasation, but may not be 
as important during implantation in the liver during metastasis. 
The therapeutic potential of uPA inhibitors and of blocking the uPA 
binding capacity on the tumour cell surface as anti-metastasic 
agents require further exploration. 
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CHAPTER 1 
INTRODUCTION 
Tumour metastasis is the spread of malignant cells from a 
pnmary tumour to a new location through either the blood stream 
or the lymphatic system to form new secondary tumours 
(metastases) [Coman 1953; Zeidman 1957; Liotta 1986a, 1992; 
Fidler 1990]. The formation of metastases is the major cause of 
morbidity and death for cancer patients. Although treatment 
modalities such as surgery, chemotherapy and radiotherapy can 
now cure approximately 50% of patients who develop a malignant 
tumour, the majority of patients in the treatment failure group 
succumb to the direct effects of metastasis or to complications 
associated with therapy. The dispersed anatomical location of 
metastases and their heterogeneous cell composition prevent 
surgical removal and limit the response to systemic anticancer 
agents [Liotta 1986a, 1992; Fidler 1990]. Therefore, there is an 
urgent need to study the fundamental biological and biochemical 
mechanisms of metastasis formation with the aim of identifying 
specific factors which may form the basis for the development of 
improved methods to predict the aggressiveness of primary 
tumours, to prevent local invasion and to identify and treat 
clinically "silent" micrometastases. This chapter will review many 
of the processes associated with the development of tumour 
metastases, particularly those which are associated with the 
expression of cell surface plasminogen activation. 
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The process of metastasis is sequential selective 
step the process containing stochastic elements. The growth of 
metastases represents the end point of many lethal events for 
malignant cells, so that only a tiny percentage ( < 1%) of tumour 
cells released from any primary tumour can survive to "seed" 
secondary sites. Both tumour cell and host factors are now 
to be intimately involved in this complicated biological 
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specific receptors c led integrins. The second step is the 
degradation of surrounding extracellular matrix (ECM) by a 
of proteolytic enzymes secreted or expressed on surface of 
"anchored" tumour cells or by neighbouring host cells under the 
influence of tumour cells. ECM lysis most likely takes place m a 
fashion which is regulated temporally and spatially and ich 
most likely occurs in a highly localised region close to tumour 
cell surface. The third step is tumour locomotion 
migration of the tumour cell out of regwn of 
3 
by proteolysis. Continued invasion of ECM (and formation of 
tertiary metastases) may take place by cyclic repetition of each of 
these steps [Liotta 1986a; Liotta et al., 1986]. 
Prior to discussing the mechanism(s) by which tumour cells 
may degrade ECM, the biochemical properties and constituents of 
ECM will be briefly outlined. 
1. 2 The Extracellular Matrix (ECM) 
1. 2.1 Biosynthesis of the ECM 
At the interface between histologically distinct tissues, the 
ECM forms highly organised structures which are organised 
through the biophysical and biochemical interactions of its 
constituent macromolecules. Prototypes of these structures are 
those located at the dermal-epithelial junction and beneath the 
capillary endothelium [Liotta et al., 1986]. One common type of 
ECM is the basal lamina, a 50 to 1 OOnm-thick structure found 
between the epithelium and adjacent connective tissues. When 
visualised by electron microscopy, most basal lamina consist of two 
distinct layers. The first of these is an electron-lucent layer (lamina 
Iucida) which is adjacent to the plasma membrane of the cells that 
rest on it,. Below the lamina Iucida lies an electron-dense layer 
called the lamina densa. In some cases a third layer (lamina 
reticularis) can be seen between the basal lamina and underlying 
interstitial stroma [Laurie et al., 1982; Kleinman et al., 1986]. 
It is generally accepted that the ECM is synthesised by the 
cells resting upon them (eg: epithelial cells for a basement 
membrane or basal lamina) or buried within them (eg: fibroblasts 
for interstitial stroma). In vitro, both benign and malignant cells 
have been found to secrete ECM [Liotta et al., 1983; Martinez-
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but they occupy a huge volume relative to their mass because 
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high anionic charge due to heparan sulphate localised m the 
basement membrane of renal glomeruli ays a crucial role m 
filtration [Martinez- Hernandez and Amenta, l 983]. 
components (eg: laminin, collagen IV and fibronectin) 
migration [M and , 1987; Azn et 
Some 
9 
8 
Transduction of signals initiating motility by these molecules 
differs depending on the type of ECM molecule encountered and 
whether the ligand is in solution or bound to a substratum 
[Aznavoorian et al., 1990b]. For example, laminin stimulates the 
attachment of neural cells and induces these cells to produce long 
thin cellular processes that resemble axons. In addition, it has been 
known that the formation of neurites is a process distinct from cell 
attachment and that it involves sites on laminin different to those 
required for attachment [Martin and Timpl, 1987]. 
1.3 ECM Alterations in Cancer 
1. 3 .1 ECM alterations in human tumours 
Changes have been reported m the histological distribution of 
basement membrane components m human cancers [Burtin et al., 
1982] In particular, marked decreases in type IV collagen 
expression and the presence of an irregular and discontinuously 
distributed basement membrane were consistently observed in 
tissue from 20 colonic adenocarcinoma samples. The basement 
membrane was also found to be defective around the tumour cells 
m both lymph node and organ metastases. [Burtin et al., 1982] 
Barsky et al. ( 1983) found that the profound changes in the 
distribution and quantity of epithelial basement membrane 
occurred during the transition from a benign tumour to an invasive 
carcmoma. In addition, although in certain regions of well-
differentiated carcinoma a basement membrane was still easily 
identifiable, abnormalities of these basement membranes were still 
apparent. Electron microscopy revealed focal defects m the 
continuity of the basement membrane lamina densa of carcinoma 
in situ. [Barsky et al., 1983]. 
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In addition, various endo- and exoglycosidases contribute to 
ECM degradation by selectively hydrolysing glycosaminoglycans 
and aminosugars [Mignatti and Rifkin, 1993]. The effects of these 
proteinases on ECM components have been extensively 
over the last decade these data have been summan a 
I 0 

Table 1.1 Extracellular matrix-degrading enzymes 
Collagen Type Proteoglycans 
Enzymes I II III IV v VII IX X Gelatins Fibronectin Laminin Elastin Protein core GAGs 
Serine proteinases 
Plasmin XXX XXX XXX XXX 
Elastases xt xt x:j: XXX XXX XXX 
Cathepsin G xt xt x:j: XXX XXX 
Metalloproteinases 
Interstitial collagenases XXX XXX XXX XXX XXX 
Type IV collagenase 
72-kDaform XXX XXX XXX XXX XXX XXX 
92-kDa form XXX XXX XXX XXX XXX XXX 
Stromelysin x§ x:j: xj: xj: XXX XXX XXX XXX XXX 
S tromelysin: 2 x:j: xj: xj: XXX XXX 
PUMP-I XXX XXX XXX 
Elastase XXX XXX XXX 
Cysteine proteinases* 
Cathepsins (B, D) xt x:j: XXX XXX XXX 
Gl cosidases XXX 
Extracellular matrix-degrading enzymes and their effects on extracellular marix components are shown. x, degradation; GAGs, glycos-aminoglycans. 
* Active only at acidic pH. t Cut only in telopeptide regions. t Cut only in nonhelical region. § Cut only in NH2-terminal region. 
(adapted from Mignatti and Rifkin, 1993) 
The involvement of proteolytic enzymes m tumour invasion 
and metastasis has been suggested for some time. Studies like 
those concerning the 65kDa type IV collagenase which was isolated 
and purified from a metastatic munne tumour and the resulting 
correlation between metastatic potential of these tumours and the 
ability to degrade basement membrane type IV collagen drew 
strong attention to this hypothesis [Liotta et al., 1979; Liotta et al., 
1980]. Using specific anti-human type IV collagenase antibodies, 
type IV collagenase antigen was revealed in the invading cancer 
cells as well as in lymph node metastases of human breast 
carcmomas [Barsky 1983]. In addition, m human colonic 
adenocarcinoma, mRNA expression of 72kDa type IV collagenase 
is higher in the pnmary tumours than m adjacent normal mucosa 
and the expression of type IV collagenase antigen levels shows a 
significant correlation with the cancer staging using the Duke's 
histological classification scheme [Levy et al., 1991]. Moreover, 
inducing the expression of tissue-type inhibitor of 
metalloproteinase-1 (TIMP-1) to inhibit the activity of type IV 
collagenase has been found to reduce the invasive and metastatic 
potential of c-Ha-ras expressing rat embryo cells [DeClerck et al., 
1992]. Suprisingly and m contrast, blocking the expression of 
TIMP-1 has been found to stimulate the invasion and metastasis of 
Swiss 3T3 cells in one study [Khokha et al., 1989]. 
Another proteolytic system thought to be strongly implicated 
tn tumour . . mvaston and metastasis IS the plasminogen 
activator/plasmin system. This thesis focusses upon the generation 
of plasmin activity on the cell surface of malignant cells and this 
system is described in great detail in the following sections. 
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of 92kDa, containing 790 ammo acids [Lijnen and Collen, 1982]. 
The full-length cDN A of human plasminogen has been cloned 
[Forsgren et al., 1987] and found to have 76% homology with 
murine plasminogen eDNA [Degen et al., 1990]. Native plasminogen 
has an NH2 -terminal glutamic acid and hence is termed Glu-
plasminogen. This form is easily converted proteolytically by 
plasmin to a modified form with lysine as the NH2-terminal 
residue (Lys-plasminogen). Lys-plasminogen has a molecular 
weight about 8kDa lower than that of the native and predominant 
Glu-plasminogen form [Lijnen and Collen, 1982]. 
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The active proteinase plasmin consists of two polypeptide 
chains held together by disulfide bonds. The light chain (B-chain) 
has a molecular weight of 25kDa and contains the active site. 
Plasmin has a relatively broad trypsin-like specificity, being 
capable of hydrolysing proteins and peptides at either lysyl and 
arginyl bonds [Danp et al., 1985]. In addition to cleaving the fibrin 
polymers of the clots formed in blood, plasmin degrades several 
components of ECM (eg: fibronectin, laminin, proteoglycan core 
proteins and vitronectin). Plasmin can also activate 
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prometalloproteinases, thereby inducing the action of other 
proteinases [Pollanen et al., 1991; Mignatti and Rifkin, 1993]. 
1. 4. 2 Plasmin inhibitors 
Plasmin is inhibited by a 2 -anti plasmin as well as other 
proteinase inhibitors (a2-macroglobulin, antithrombin III, a 1-
antitrypsin and Cl-inhibitor) which interact with plasmin to form 
inhibitor-plasmin complexes. Among these inhibitors, a2-
antiplasmin is believed to be the most important plasmin inhibitor 
in vivo [Levi et al., 1993]. a 2 -anti plasmin is a single-chain 
glycoprotein with a molecular weight of 70kDa. The concentration 
of a 2 -anti plasmin tn pooled normal human plasma is 
approximately 1 !1-M. Plasmin-a2 -antiplasmin complex formation 
occurs by strong interactions between the light-chain of plasmin 
and the inhibitor in at least two steps. The first is a very fast, 
reversible second order reaction which is followed by a slower, 
irreversible first order reaction. The rate of the reaction is strongly 
dependent on the availability of free lysine-binding sites and a 
free active site in the plasmin molecule [Collen and Wiman 1978; 
Lijnen and Collen, 1982]. Since these sites are also involved in the 
binding of plasminogen and plasmin to fibrin [Collen and Wiman 
1978] , ECM or cell surfaces [Ellis et al., 1991; Stephens et al., 1989; 
Hall et al., 1991] bound plasmin has been found to be "shielded" 
from inhibition by a2-antiplasmin. 
1. 4. 3 Plasminogen activators 
Enzymes which activate plasminogen to plasmin (plasminogen 
activators) are found in most tissues and fluids and exist in two 
distinct forms, namely tissue-type plasminogen activator (tPA) or 
urokinase-type plasminogen activator (uPA). These two distinct 
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subsequently cleaves sctPA into tctPA, thus amplifying the 
reaction by activating more plasminogen. In contrast to 
plasminogen, the binding of tPA to fibrin is mediated both by its 
"finger" and its "kringle 2" domains [Lijnen and Collen, 1982; 
Hoylaerts et al., 1982; Rijken et al., 1982; Dan!Z) et al., 1985; de 
Vries et al., 1991]. Since tPA is only poorly active in the absence 
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Single-chain uPA (scuPA) IS a protease zymogen [Ellis et al., 1987; 
Stephens et al., 1987; Lijnen et al., 1990] that can be converted into 
the active or two-chain uPA (tcuPA) form by plasmin which 
cleaves the Lysi58-Ileui59 peptide bond on the heavy or B chain. 
TcuPA can be further cleaved by plasmin resulting in an 30-33kDa 
form of uP A (often referred to as low-molecular weight uP A). The 
low-molecular weight form of tcuPA contains the complete heavy B 
chain but lacks most of the light A chain including the 
it not et 
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55-60kDa and is a single-chain glycoprotein [Nielsen et ' 1988; 
Estreicher et , 1989; Behrendt et al., 1990]. NH2-terminal 
sequence data [Behrendt et al., 1990] allowed the construction of 
an oligonucleotide probe and the isolation of a full-length cDN A 
coding for uPAR [Roldan et al., 1990]. The deduced amino acid 
sequence predicts a polypeptide of 313 amino acids, in good 
agreement with the apparent molecular weight of 35kDa of the de-
glycosylated receptor [Behrendt et al., 1990]. uPAR is known to be 
post-translationally processed at the C-terminus to give a molecule 
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[Kirchheimer et al., 1987a, b; He et al., 1991; Rabbani et al., 1990, 
1992]. 
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Figure 1.1 A schematic model of the inactive one-chain 
proenzyme form of human uP A 
The Lys158-1Ie159 peptide bound is cleaved by plasmin during the 
conversion of single chain pro-uPA to two-chain active uPA. Cleavage at the 
second site, indicated by the second arrow, results in an amino-terminal 
fragment and "low-molecular-weight uPA" that retains catalytic activity. 
(adapted from PolHinen et al., 1991.) 
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1.4.3.4 Receptor-bound uPA & cell surface 
plasminogen activation 
Ellis et al. (1987, 1989) reported that the binding of both 
scuP A and plasminogen to cells which express high levels of uP AR 
on their surface (U937 cells) but undetectable levels of endogenous 
uPA facilitated scuPA activation and the consequent formation of 
plasmin. This potentiation of plasminogen activation was 
completely abolished by the addition of either 6-aminohexanoic 
acid or the amino-terminal fragment of uP A (ATF) [Ellis et al., 
1987, 1989], indicating that both uP A and plasminogen must be 
bound to the cell surface of these cells for accelerated plasminogen 
activation to occur. 
In other cell types (eg: the epidermoid carcinoma cell line 
A431 and the fibrosarcoma cell line HT -1 080) cell surface uPARs 
are saturated with endogenous scuP A [Stoppelli et a!., 1986; 
Stephens et al., 1989]. When HT1080 cells were incubated with 
Glu-plasminogen, plasmin was generated on the cell surface and 
receptor-bound scuP A was converted into high molecular weight 
tcuP A, even m the presence of serum-containing plasmin 
inhibitors. Again, binding of plasminogen to cell surfaces was an 
essential requirement [Stephens et al., 1989]. The human uPAR 
gene is located on chromosome 19 [Vagnarelli et al., 1992]. 
Binding to its specific cell surface receptor has no direct effect 
on the catalytic activity of tcuPA. In contrast, the kinetics of the 
activation of plasminogen by uPAR-bound tcuPA is more efficient 
2 1 
than that which occurs in the soluble phase (Km = 0.67 j.!M for 
receptor-bound tcuPA-mediated activation compared to a Km = 
25j.!M for soluble phase activation). Activation of ~H-&urjace ~ocia:had 
plasminogen by uPA bound to uPAR is well below the physiological 
plasminogen concentration (21l M) of plasminogen. This high 
affinity plasminogen activation also depends upon the binding of 
plasminogen to the cell surface [Ellis et al., 1991]. The combined 
effects of accelerated plasmin generation and prolonged plasmin 
action through resistance to inhibition by circulating inhibitors 
results m a highly effective cell surface-bound proteolytic system 
[Stoppelli, et al., 1986; Ellis and Danf<:'S 1991; PolHinen et al., 1991; 
Vassalli et al., 1992]. 
1. 4. 4 Plasminogen activator inhibitors 
Plasminogen activator inhibitors (PAis) belong to the serine 
v..roteinase inhibitor (serpin) superfamily and to the subgroup 
termed argmme or Arg-serpins (based upon the presence of 
argmme residues at the P 1 position in the primary sequence of the 
"reactive centre loop" of the inhibitor. Currently there are four 
known classes of plasminogen activator inhibitors: PAI-l, PAI-2, 
PAI-3 and proteinase nexin I. Of these four classes, PAI-l and 
PAI-2 are highly specific for PAs, whereas PAI-3 and proteinase 
nexin I have much broader protease specificity profiles [Vassalli e t 
al., 1991; Pollanen et al., 1991]. 
1.4.4.1 PAI-l 
The production of PAI-l was originally described m 
endothelial cells and its production has since been reported from a 
wide variety of cell types. PAI-l is also present in human plasma 
[Vassalli et al., 1991; Pollanen et al., 1991]. PAI-l is a single-chain 
46-54 kDa glycoprotein encoded by either 3.0 and 2.2 Kb mRNAs 
with the shorter transcript possibly being generated by modified 
polyadenylation. The human PAI-l gene of 12.2 kb and is located 
on chromosome 7. The amino acid sequence deduced from the 
PAI-l eDNA contains 379 residues, three potential glycosylation 
sites but no cysteine residues. The active centre is located in the 
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the 60kDa form is found extracellularly. Much of the P AI -2 
synthesised by a cell appears to accumulate intracellularly. The 
PAI-2 cDN A encodes a protein containing 415 amino acids, the 
predicted amino acid sequence of the placent and 
monocyte/macrophage forms being identic PAI-2 gene is 
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located on chromosome 18 [ et al., 1987; et al., 1989; 
Vassalli et al., 1992]. PAI-2 is primarily a rapid inhibitor of uPA. It 
has limited capacity to tPA compared to PAI-l. PAI-2 reacts with 
high molecular weight tcuPA (55kDa) and low molecular weight 
uP A (3 3kDa) but not scuP A [Astedt et al., 1985; Stephens et al., 
1985; Stephens et al., 1987]. There are important differences 
between PAI-2 and PAI-l that are relevant to their potential for 
regulating uPA activity in the invasive process. One of the 
differences Is the prolonged functional stability of PAI-2 m the 
soluble phase compared to the rapid inactivation of P AI -1. The 
more important distinction relates to the specificity of PAI-2 for 
tcuPA compared to the broader inhibitory capacity of PAI-l which 
rapidly inhibits both forms of tP A as well as tcuP A [PolHinen et al., 
1991]. 
1. 4. 5 Regulation of cell surface pathway of 
plasminogen activation 
The cell surface plasminogen activation cascade is controlled 
by two major events. these are (1) the binding of plasminogen to 
specific sites on the cell surface and (2) the regulation of cell 
surface receptor-bound uPA activity. Each of these will be now be 
addressed separately. 
1.4.5.1 Cell surface plasmin and plasminogen 
receptors 
As discussed above, plasminogen binding to cell surfaces 
results m enhanced plasminogen activation, localisation of the 
proteolytic activity of plasmin on cell surfaces and protection of 
plasmin from a2-antiplasmin [Stephens et al., 1989; , Polltinan e t 
al., 1991; Vassalli et al., 1991; Miles et al., 1991]. Therefore, 
plasminogen receptors are involved in the regulation of cell 
surface plasminogen activation. The existence of plasminogen 
24 
receptors was originally demonstrated on platelets [Miles and 
Plow, 1985]. These cells were shown to bind plasminogen in a 
time-dependent and saturable manner and with a precise 
recognition specificity such that unrelated proteins or other 
zymogens of senne protases failed to interfere with the 
interaction. Similar interactions were then documented to occur 
with a wide variety of other cell types [Miles et al., 1991; 
Stephens et al., 1989; Burtin and Fondaneche, 1988]. It has been 
found that both proteins and nonprotein cell surface constituents 
function as plasminogen binding sites. Gangliosides, components of 
the outer leaflets of cell membranes, exhibit the appropriate 
properties of the non-protein plasminogen receptors [Miles et al., 
1989; Plow and Miles, 1990]. As suggested by Miles et al. ( 1991) 
that protein receptor of plasminogen may be a group of cell-
surface proteins sharing a common feature, so called carboxy-
terminal lysyl residues. A 54kD cell-surface plasminogen binding 
protein has been purified from U937 monocytoid cells and 
identified as a-enolase. Carboxy-terminal lysyl residues are found 
responsible for a-enolase binding plasminogen [Miles et al., 1991 ]. 
1.4.5.2 Regulation of cell surface 
bound uP A activity 
receptor-
Cell surface receptor-bound uPA activity may be regulated at 
many levels within the cell. These include: 
• rates of de novo uPAR, uPA and PAis gene expression and 
transcription 
• relative stabilities of mRNAs for uPAR, uPA and PAis, 
• binding efficiency of scuP A to cell surface uP AR, 
• occupancy rates of uP AR with scuP A, 
• rate of activation of uPAR-bound scuPA, 
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Table 1.2 Agents that modulate (mRNA & protein) components of the uPA system in vitro 
uPA uPAR PAI-l PAI-2 
mRNAiprotein mRNAiprotein mRNAiprotein mRNAiprotein 
PMA +I+ +I+ +I+ +I+ 
Butyrate - I - - I - +I+ ND 
Glucocorticoids 
-1-; =I= =I= +I+; -1- - I -
HF +I+ ND/- ND ND 
HGF +I+ +I+ ND ND 
TGF~ =I=; +I+ ND +I+ ND 
TNFa. +I+ +I+; +I= +I+ +I+ 
IFNy +I+ - I - ND =I= 
M-CSF =I= +I+ ND +I+ +I+ 
IL-l =I= =I= +I+ ND 
+, increase; =, no effect; -, decrease; ND, not determined. 
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Receptor-bound scuPA can be converted into active tcuPA on 
cell surfaces by receptor-bound plasmin. As mentioned earlier, s 
reaction is not inhibited by a2 -anti plasmin but it can be inhibited 
by either the low molecular weight inhibitor aprotinin (TrasylolR) 
or an anticatalytic monoclon antibody against human pl n 
[Stephens et , 1987]. Receptor-bound tcuPA retains its 
activity against plasminogen and it also retains to react 
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with, and be inhibited by, PAI-l and PAI-2 [Stephens et al., 1987; 
Ellis et al., 1990] albeit at higher molar effectiveness than occurs 
m solution phase [Baker et al., 1990]. 
The complexes of tcuPA and PAI-l or PAI-2 formed on cell 
surfaces or formed in solution which are then bound to cell 
surfaces (eg: through uPAR), can be internalised quickly and then 
degraded in lysosomes. Although not completely understood at this 
time, this reaction appears to involve both uP AR and the cell 
surface low density lipoprotein receptor-related protein (LRP = 
a 2 macroglobbulin receptor) m some cells. Clearly, this 
phenomenon is confined to cells that express both uPAR and a 
functional LRP system [Estreicher et al., 1990; Nykjaer et al., 1992; 
Herz et al., 1992]. It also appears that after internalisation the 
uP A:P AI complexes are dissociated from uP AR under acid 
conditions and uPAR is recycled to the cell surface while uPA:P AI 
complexes are degraded within the acidified lysosomes [Herz et al., 
1992]. 
1 . 5 The Role of uP A/plasmin System in Tumour 
Invasion and Metastasis 
A great body of evidence has accumulated over recent years 
to suggest that invasion and metastasis in solid tumours requires 
the action of tumour-associated proteinases that promote the 
dissolution of the surrounding tumour matrix and the basement 
membranes and assist in angiogenesis. The uPA/plasmin system 
appears to play a critical role in these events. 
1. 5.1 Occurrence of uP A and/or uPAR in cancer 
In Lewis lung carcinomas, increased uPA antigen has been 
localised by immunocytochemical techniques to areas with 
invasive growth and degradation of surrounding normal tissue 
[Skriver et al., 1984]. Immunostaining using anti-uPA antibodies 
has revealed that increased antibody uptake in the "invading 
front" of the tumour (both m primary and in metastatic lesions) in 
xenografts of the human prostate carcmoma cell line (PC-3). 
Similar patterns are found with surgically removed human 
prostate carcinoma resections [Kwaan et al., 1991 ]. Urokinase 
antigen was localised at the "invading front" of human colon 
cancers by immunoperoxidase staining [Kohga et al., 1985]. Using 
in situ hybridization methods, it was shown that uP A is expressed 
m the stromal cells and its receptor in cancer cells at invasive foci 
in human colon adenocarcinomas [Pyke et al., 1991 a]. Despite these 
observations, there is currently quite lively discussion about where 
and in which cells uPA antigen is localised in different types of 
cancer [Pyke etal., 1993a]. 
1. 5. 2 Correlation between tumour stage and the 
levels of uPA content 
Sim et al. ( 1988) reported that there was a significant 
correlation between the stage of invasiveness and the levels of 
scuPA content in human colon cancers determined by uPA activity 
assay. In another report, a I 0-fold increase in uP A antigen was 
found m colon carcinomas as compared with normal tissue [de 
Bruin et al., 1988]. Sappino et al. (1987) determined the uP A 
mRNA levels in a prospective series of 29 primary lung tumours 
and 27 primary breast carcinomas. Most tumours had a uPA mRNA 
content significantly higher than the mean of nonmalignant tissue 
counterparts. A large (4- to 20-fold) mcrease in uPA mRNA was 
found in 14 of the 29 lung carcinomas and in I 0 of the 27 breast 
carcmomas examined. Moreover, a statistically significant 
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correlation was also found between elevated uPA mRNA content in 
human lung carcinomas and the presence of regional lymph node 
metastases [Sappino et al., 1987]. 
In human breast adenocarcinoma, it has been established that 
uP A as well as PAl -1 antigen levels m the tumour biopsies were 
independently associated with increased rates of relapse and lower 
overall survival rates. By contrast, patients affected with breast 
adenocarcinomas displaying high levels of tP A had a significantly 
longer disease-free interval and survival than patients whose 
tumours had lower levels of tPA [Duffy et al., 1986, 1988, 1990; 
Janicke and Schmitt, 1991; Foe-kens et al., 1992]. 
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1. 5. 3 Inhibition of tumour cell line mediated ECM 
degradation 
Generally, tumours with high metastatic potential or cell lines 
which are highly metastastic in in vivo models of metastasis (see 
below) demonstrate a strong ability to degrade ECM in vitro [Albili 
et al., 1988; Mignatti and Rifkin 1993]. Plasminogen-dependent 
ECM degradation by HT -1080 cells was initiated by uP A, required 
plasminogen, could be inhibited by human PAI-l and was 
enhanced by the presence of antibody directed against human 
PAI-l [Cajot et al., 1990]. Two selected human colon cancer cell 
lines (COL0394 and LIM 1215) degraded labelled human umbilical 
vem endothelial cell ECM in a time- and plasminogen-dependent 
manner which was inhibitable by human PAI-2 and TrasylolR 
[Baker et al., 1990]. 
1. 5. 4 Receptor-bound uP A is essential to tumour 
invasion 
In vitro ECM degradation and Matrigel invasion studies 
indicate that cell surface receptor-bound uPA is essential to 
tumour invasion in many systems. Hollas et al. ( 1991) reported 
that among selected colon cancer cell lines, the ability to invade 
Matrigel was correlated with the amount of receptor-bound uPA 
on the cell surface. Blocking the endogenous binding of scuPA to 
uPAR on cell lines which expressed very high receptor-bound uPA 
levels (using an antibody against the A chain of uPA) reduced the 
invasiveness of this cell line. In agreement, using the cell line with 
the least uP AR and inducing this line to increase uP A secretion by 
-8 fold in response to an exogenous uPA gene driven by the Rous 
sarcoma virus long terminal repeat promoter failed to augment its 
ability to invade Matrigel. In a cell line with a large proportion of 
unoccupied uPAR, preincubation with exogenous uPA to occupy the 
majority of these binding sites resulted in increased Matrigel 
invasion [Hollas et al., 1991]. When HCT116 (human colon cancer 
cell line) cells and PC3 (human prostate carcinoma cell line) cells 
were genetically engineered to express an inactive mutant uPA to 
compete with endogenous native uPA for occupancy of uPAR, cell 
surface plasminogen activation was inhibited and ECM degradation 
or Matrigel . . mvas10n by these genetically-engineered cells 
decreased dramatically [Cohen et al., 1991; Crowley et al., 1993]. 
1. 5. 5 Metastatic potential and receptor-bound 
uP A 
In vivo experimental evidence supporting the involvement of 
receptor-bound uPA in tumour invasion and metastasis is much 
less well documented than that reported from in vitro studies. In 
vivo evidence falls into three main experimental regimes where 
results show: 
(1) correlation between receptor- bound uP A expression and 
metastatic behaviour, 
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is known to convert receptor-bound scuPA into active tcuPA, 
increased the incidence of experimental metastasis by 200-300% 
[Hearing et al., 1988]. Moreover, the spontaneous metastasis 
human PC3 prostate carcinoma cells was significantly 
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all of the target organs, when receptor-bound scuPA on the cells 
surface was replaced with inactive mutant uPA by transfecting 
these cells with a plasmid encoding a mutant uP A (Ser356~ Ala) 
eDNA [Crowly et al., 1993]. 
1. 6 Experimental Models of Metastasis 
There are two common approaches for studying the 
biochemistry and cell biology of the process of tumour metastasis. 
The first involves selecting variant, related tumor cell lines with 
differing in vivo metastatic potential and subsequently comparing 
high and low metastatic cell lines in vitro for some other 
characteristic (eg: enzyme production, enzyme secretion, enzyme 
binding, receptor expression, presence/changes m adhesion 
molecule expression (eg: integrin or cahedrin)). The aim of these 
studies is to establish a correlation between metastatic behaviour 
in vivo and particular biological properties. The second strategy is 
to select or produce biologically or genetically variant, related 
tumour cell sublines with elevated or decreased expression of a 
specific in vitro characteristic, (eg: motility, proteinase production, 
receptor expression) and then to assess the behaviour of the 
particular sublines in vivo and hopefully to identify the specific 
characteristics contributing to metastatic behaviour [Hart 1982; 
Liotta 1986b; Fidler 1990]. In order for these approaches to be 
valid it appears that both in vitro and in VlVO data are required 
and that both experimental models are capable of providing useful 
data on concernmg the cell biology of tumour invasion and 
metastasis. 
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1.6.1 In . VlVO models of metastasis 
Most in vivo data concerning the biology of tumour metastasis 
is generated from studies using animal models of metastasis. To 
study human tumour cell metastatic potential, two kinds of animal 
models are currently available and favoured: 1) transplantation of 
tumour cells into chick embryos and 2) transplantation, 
implantation and injection of tumour cells into athymic, 
immunosuppressed mice (eg: nude or scid (ie: severe combined 
immuno-deficient) mice). The advantage and the limitations of 
each of these models of metastasis are reviewed in the following 
sections. 
1.6.1.1 Transplantation of human tumour in 
chick embryo 
Dagg et al. ( 1956) reported that human tumour cells 
transplanted to a chick embryo metastasised from either the 
chorioallantoic or the yolk sac to the chick embryo itself. 
Transplantation of tumour cells onto the chorioallantoic membrane 
(CAM) has proved to be a successful model of tumour metastases 
because the chick embryo is a naturally immunodeficient host and 
can accept transplantation of variety of human tissues and cells. A 
second advantage is that tumour invasion and angiogenesis of 
blood vessels can be easily observed [Ossowski and Reich, 
1980,1983; Ossowski 1988a,b, 1992; Armstrong et al., 1982; 
Folkman et al., 1983]. Several studies concerning the role of uPA 
and uP AR m tumour invasion and metastasis have been performed 
using this m vivo model [Ossowski and Reich, 1980,1983; 
Ossowski 1988a,b, 1992], which has also been used it to investigate 
tumour angiogenesis [Folkman et al. 1983]. The major 
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disadvantage of this model is the brief experimental "window" 
provided by the time limitation of 7-10 days imposed due to the 
development of the embryonic immune system. Most human 
tumours cannot produce macroscopic metastatic lesions in this 
limited time period. To overcome this disadvantage, Chambers e t 
al. (1982) modified the model by injecting tumour cells into the 
CAM vein instead of implanting them directly onto the CAM. 
Tumour cell growth or death in a target organ was determined by 
dissecting out the target organ, dissociating it into a suspension of 
single cells and then plating these cells in vitro in medium 
containing a concentration of ouabain sufficient to kill chicken cells 
while permitting growth of any tumour cells present [Chambers e t 
al., 1982; Chambers 1986]. While sensitive and quantitative, this 
method 1s not suitable for studying tumour invasion and 
angiogenesis which is thought to be better studied by prelabelling 
tumour cells with [ 125 I]iododeoxyuridine and then quantitating 
tumour invasion by monitoring the radioactivity which is found 
inside the CAM [Ossowski 1988b, 1992]. 
1.6.1.2 Transplantation of human tumour cells 
into athymic nude mice 
Since the initial observation by Rygaard and Povlson (19 6 9) 
that xenogeneic human tumours could grow in athymic ("nude") 
mice, intensive efforts have been made to use this in vivo model 
for studies into the mechanisms of tumour metastasis. The growth 
and metastasis of human tumours transplanted into athymic nude 
mice is dependent on many host and tumour-related properties, 
including the origin and type of tumour, the route of inoculation 
and the age, strain and state of health of the recipient mice [Hanna 
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1982]. Some of these parameters will be discussed in subsequent 
sections. 
1.6.1.2.1 Subcutaneous implantation 
Most human cancers grow in nude mice after subcutaneous 
implantation but the growth of these transplanted tumours is not 
always associated with metastasis. Melanoma [Kozlowski et al., 
1984a,b; Yagel et al., 1989; Quax et al., 1991], large cell lung 
carcinoma [Cole et al., 1986], breast carcinoma [Giovanella and 
Fogh, 1985] and prostate cancer [Crowley et al., 1993] however 
spread readily after subcutaneous implantation in nude mice. By 
contrast pancreatic adenocarcinoma [Kajiji et al., 1982] and renal-
cell carcinoma [Kozlowski et al., 1984b; Straroselsky et al., 1992] 
have a much lower metastatic rate and some human tumours, such 
as, colon cancer, rarely metastasise after subcutaneous 
transplantation [ Rygaard and Povlson, 1969; Fidler 1990]. 
1.6.1.2.2 Intravenous injection 
Generally, the frequency of metastasis IS greatly enhanced 
after using intravenous rather than subcutaneous inoculation of 
tumour cells [Kozlowski et al., 1984a, b; Giavazzi et al., 1986a,b; 
Yagel et al., 1989; Quax et al., 1991]. An obvious feature of this 
"experimental" model is that intravenous injection of tumour cells 
bypasses the initial steps of the metastatic process. Thus, this 
model examines the late steps of the process namely, release of 
tumour cells into the circulation, arrest of tumour cells m capillary 
beds, extravasation of tumour cells into the target organ and the 
growth of cells in the target organ [Hanna 1982]. 
1.6.1.2.3 Orthotopic transplantation 
Orthotopic transplantation of human tumour cells or tumour 
tissue into nude mice enhances the growth and the metastasis in 
colon cancer [Giavazzi et al., 1986a,b; Bresalier et al., 1987; 
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In this method radioactively labelled or fluorescently labelled 
purified ECM components (eg: fibronectins, laminin and interstitial 
or type IV collagen) are immobilised either singularly or .in 
combination as a degradable substrate. Cancer cells are 
subsequently grown and degrade this substrate, causing the 
release of soluble degradation products into the culture medium 
[Liotta et al., 1979, 1980; Schlechte et al., 1989]. With fluorescence 
labelling degradation of ECM is revealed as negative fluorescence 
areas indicating substantial degradation of the substrate [Chen 
1985]. Because biochemically defined components are used, this 
model allows for a detailed study of the types of substrate(s) 
degraded, the size and sequence of degradation products and the 
indentification of enzyme(s) involved in the process of ECM 
digestion by a particular tumour cell [Mignatti and Rifkin, 1993]. 
1.6.2.2 Degradation of radiolabelled ECM by 
tumour cells 
Radioisotopically labelled ECM can be formed metabolically in 
vitro by growing cells (eg: endothelial cells, smooth muscle cells, 
fibroblasts or some tumour cells) in the presence of radioactive 
precursors for several days. The ECM-producing cells are then 
removed, leaving an insoluble layer of ECM on a plastic substrate. 
Tumour cells cultured on these labelled ECMs release soluble 
degradation products into the medium [Jones and DeClerck, 1980; 
Baker et al., 1990; Cajot et al., 1990; Cohen et al., 1991; Quax et al., 
1991]. Although this model is re1ati vely simple, the 
macromolecular composition and the structure of the metabolically 
labelled ECM may vary depending on the cell type used to produce 
a specific ECM [Mignatti and Rifkin, 1993]. 
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1.6.2.3 MatrigeiR invasion assay 
Matrigel is a commercially available reconstituted basement 
membrane anaologue which is prepared from ECM components 
extracted from the EHS (Englebreth-Holm-Swarm) sarcoma 
[Kleinman et al., 1986] and which has been used extensively to 
prepare an in vitro invasion assay substrate. In this assay 
polycarbonate filters with pores of 5-8 J.Lm in diameter are coated 
with Matrigel and this is used as the barrier in a Boyden chamber 
device. Both compartments of the chamber are filled with culture 
medium and the tumour cells are seeded on the top of Matrigel-
coated filter. During the culture period, the invasive cells degrade 
the Matrigel and can migrate through the pores of the filter. In 
contrast, non-invasive cells can not degrade the Matrigel-coated 
filters. At the end of the culture, the Matrigel on the top of the 
filter is removed, the filter is stained and the number of cells on 
the bottom face of the filter is counted [Albini et al., 198 8]. This 
model has been used to test the invasiveness of human prostate 
and colon cancer cell lines [Crowley et al., 1993; Hollas et al., 1991 ]. 
Some of the limitations of the Matrigel invasion model are: ( 1) 
Matrigel lacks the resilience and consistency typical of in vivo 
basement membranes [Kleinman et al., 1986], and (2) the 
reproducibility of Matrigel invasion assays ts often affected by 
variations in substrate preparation [Mignatti and Rifkin, 1993]. 
1.6.2.4 Degradation of natural basement 
membranes 
Three different types of natural basement membranes have 
been used for invasion studies: the human amniotic membrane, the 
bovine lens capsule and the chorioallantoic membrane (CAM) of 
the chick embryo (as described previously). The human amniotic 
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1 Scope and Objectives This 
Invasion is the ability of tumour cells to cross anatomic 
barriers including various types of ECMs into surrounding tissues 
and is thought to represent one of the critical events involved 
the multistep process of tumour metastasis. Proteolytic enzymes 
such as type IV collagenase, uPA and 
tumour cells to degrade the ECM. 
are req 
4 
Evidence has accumulated to suggest that the cell surface 
plasminogen activation pathway is central to the tumour invasion 
process. ScuP A produced by tumour cell or stromal cells .is 
captured by specific receptors on the tumour cell surface where 
cleavage by receptor-bound plasmin generates active receptor-
bound uPA which, in turn, initiates the proteolytic cascade by 
activating receptor-bound plasminogen to plasmin. Plasmin then 
degrades components of tumour stroma and the basement 
membranes and may activate procollagenase IV to degrade 
collagen IV. Cell surface plasminogen activation therefore appears 
to promote the dissolution of the ECM thereby permitting tumour 
invasion and metastasis (See Figure 1.2). 
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Figure 1.2 A diagram of tumour cell surface pathway 
plasminogen activation and subsequent extracellular 
matrix degradation 
On tumuor cell surface, receptor-bound pro-uPA is converted into 
active uPA by receptor-bound plasmin. Receptor-bound active uPA, in turn, 
catal1zes receptor-bound plasminogen to generate more plamin which 
attacks the components of the ECM directly, or indirectly by activating other 
pro-proteases such as pro-collagenase IV. The activation of receptor-bound 
plasminogen by receptor-bound uPA can be inhibited by plasminogen-
activator inhibitors (PAis) such as PAI-l and PAI-2. 
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To block the expression of uPAR, HCT116 cells (one of the 
highly metastatic cell lines) were transfected with a plasmid 
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CHAPTER 2 
ENDOGENOUS RECEPTOR-BOUND uPA ACTIVITY AND 
THE POTENTIAL OF COLON CANCER CELLS TO 
ACTIVATE PLASMINOGEN 
2.1 Introduction 
As reviewed in Chapter 1, strong evidence suggests that the 
plasminogen activation system may be involved in the process of 
tumour metastasis by initiating focal proteolysis of ECM thereby 
permitting tumour cells to penetrate surrounding normal tissues 
and spread to distant organs. Moreover the activation of 
plasminogen on tumour cell surfaces by receptor-bound uPA 
represents one of the sites at which the regulation of the 
proteolytic events that characterise invasion may occur. A number 
of human tumour cell lines including A431 (epidermoid 
carcinoma), HT -1080 (fibrosarcoma), PC3 (prostate carcinoma), 
MV3 and BLM (melanoma) and HCT 116 (colon cancer) express both 
uP AR and uP A during tissue culture. In such cell lines, the cell 
surface uPAR are occupied by endogenous uPA in an autocrine 
fashion and have the potential to activate plasminogen on their 
surface. 
The biological importance of receptor-bound uPA has 
generated the need for a convenient assay of cell surface uP A 
activity. The methods used to assess receptor-bound uPA in recent 
years, involved recovering receptor-bound uPA from cell surface 
uPAR by "acid elution" and then determining the level of uP A 
antigen tn the eluates usmg an enzyme-linked sandwich 
Immunoassay [Schlechte et al., 1989], or by immunoprecipitating 
uP A from the eluates and assaying uP A activity [Stephens et al., 
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1989; Cohen et al., 1991; Crowley et al., 1993]. These multi-step 
methods are specific but they are both cumbersome and time 
consuming. In order to undertake studies aimed at examining t~e 
role of cell surface bound uPA activity, the development of a new 
convenient assay of receptor-bound uPA activity on viable 
adherent cells was required . This chapter describes: 
• the development of a biochemical assay that is both specific and 
sensitive for the determination of cell surface receptor-bound 
uPA activity on viable adherent cells 
• the characterisation of a range of human colon cancer cell lines 
(in terms of their endogenous receptor-bound uPA and uPA 
activity and total uP A-binding (ie:uPAR) capacity. 
2. 2 Materials & Methods 
2.2.1 Materials 
The peptide substrates Glu-Gly-Arg 4-aminomethyl coumann 
(GGA-AMC) and H-D-Val-Leu-Lys 4-aminomethyl coumarin (VLL-
AMC) were obtained from Bachem Feinchemikalien AG, Germany. 
Human urokinase (Actosolv, high molecular weight uPA > 90%) was 
a kind gift from Dr Erquart Schuller, Behringwerke, Marburg, 
Germany. Standard high molecular weight uP A (# 124, 55 kDa, 
-3,000 IU/vial), human plasmin (product # 421, containing greater 
than 95% active sites, 40 CU/mg and 0.5 mg/vial), munne 
monoclonal-antibody against human uP A (MAb#394) and goat 
anti-human melanoma tPA IgG (MAb #387) were purchased from 
American Diagnostica Inc., Greenwich, USA. Lysine-Sepharose, 
NAP-I 0 columns (containing Sephadex G-25) and pre-stained high 
and low Mr standards were obtained from Pharmacia, U ppsala, 
Sweden. [125 I]-Na and materials for the ECL Western blotting 
detection system (including: nitrocellulose membranes, HRP-
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antiplasmin) based upon a published procedure [Deutsh and Mertz, 
1970]. 
2.2.3 Human colon cancer cell lines and cell culture 
Human colon cancer cell lines, HCT 116 and LS 123 were 
obtained from the American Type Tissue Collection (ATCC); 
LIM1215 was obtained from Dr. R. Whitehead (Melbourne Tumour 
Biology Branch, Ludwig Institute for Cancer Research, Melbourne); 
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KM12SM cells were a kind gift from Prof. I.J. Fidler (M.D. Anderson 
Cancer Centre, Houston, Texas, USA.). 
HCT 116 cells and LIM1215 cells were cultured in RPMI 1640 
medium containing 10% fetal calf serum (FCS), 4mM L-glutamine, 
50~g/ml gentamycin and 60~g/ml penicillin. KM12SM cells and 
LS 123 cells were cultured in Eagle's MEM with Hanks' salts 
supplemented with non-essential amino acids, sodium pyruvate, 
MEM vitamin solution, 10% FCS, 4mM L-glutamine and 50 ~g/ml 
gentamycin. All of the cells were incubated at 370c in a 5% C02 
incubator. 
All of the cell lines were free of mycoplasma (as assessed 
usmg Hoechst stain # 33258) and were tested for vtrus 
contamination by transmission electron microscopy of all cell 
cultures periodically (ie: - every 6months) throughout this study. 
2.2.4 Protein assay 
Protein concentration of samples was determined usmg the 
Bio-Rad protein assay, a protein-dye binding assay [Bradford 
1976]. Bovine serum albumin was used as a standard. 
2.2.5 Radio-iodination of urokinase 
H M r human uP A (Actosolv 600,000R) was radiolabelled with 
Na-125J by the Iodo-bead procedure [Markwell 1982]. Briefly, 5 ~~ 
of Na-125J (0.5 mCi) was diluted with 10 ~I of O.IM Tris-HCI pH 8.0 
and 55 ~I of PBS. Two pre-washed and dried Iodo-beads were 
added into the mixture and incubated at room temperature for 5 
min. Then, 300 ~I of uPA (300~g total) was introduced into the 
reaction vial and mixed well. The reaction was allowed to continue 
at room temperature for 12 min. The volume of the mixture was 
adjusted to 1ml with another 630 ~1 PBS before it was transferred 
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onto a NAP-10 column previously equilibrated with PBS. Proteins 
were eluted with PBS. The first l.Sml of eluate [which represented 
macromolecular (protein-bound) 1251] was collected and stored at 
4 0 C. Each preparation was used within two weeks of radio-
iodination. The specific radioactivity of the preparations was 
between 750-1000 cpm/n g protein. Free 125J in the preparations 
was less than 10% as determined by trichloroacetic acid (TCA) 
precipitation of radioactivity from the preparations. 
2.2.6 Receptor-bound uPA activity (indirect) assay 
Receptor- bound uP A activity on the surface of adherent colon 
cancer cells was determined fluorimetrically by monitoring the 
release of free 4-aminomethyl coumarin (AMC) from the peptide 
substrate H-D-Val-Leu-Lys 4-aminomethyl coumarin (VLL-AMC) 
in 50mM Tris-HCI pH 8.0, containing O.IM NaCI [Ellis et al., 1990]. 
Initially, the peptide was dissolved in a small volume of DMSO and 
then in 50mM Tris-HCI 0.1 M NaCI, pH 8.0 (assay buffer) to fonn a 
lmM working solution. After culture of the colon cancer cells as 
above and before the uP A activity assay, the cells were washed 
twice in situ with assay buffer (50mM Tris-HCl pH 8.0, 0.1 M NaCl). 
Cell surface uPA activity was measured by incubating cells at 370C 
for 1-4h with lOOjlM VLL-AMC and 2jlg/ml purified human 
plasminogen m 50mM Tris-HCl pH 8.0, containing O.IM NaCI. After 
appropriate incubation times, assay reagents were transferred to 
black microtitre plates which contained 10111 of TrasylolR (1 0 KIU) 
to stop further cleavage of VLL-AMC. Fluorescence was measured 
using excitation 355nm and emission 460nm In a Flow 
Laboratories "Titertek" Fluoroskan II plate-reader. Although the 
optimal wavelengths to measure release of 4AMC are 370nm I 
460nm, little sensitivity is lost with the small change in excitation 
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wavelength. Fluorescence intensity was calibrated to standards in 
every individual experiment using purified high Mr human uPA 
over the range 25-4000miUiml, due to daily variation m the 
fluorescence intensity produced by uPA standards. 
2.2. 7 Acid elution procedure 
Partial elution of potential ligands from the surface of colon 
cancer cells was conducted on cells, grown as above, after 2 washes 
with serum-free medium (SFM) by an established procedure 
[Stoppelli et al., 1986]. Colon cancer cells were exposed to a pre-
chilled (4 OC) acidic buffer (50mM glycine I HCI pH 3.0, containing 
O.IM NaCl) for 3min and then neutralised with 1 l5 volume of 0.5 
M HEPES pH 7.5 containing O.IM NaCl for lmin. Medium was 
removed quickly from the plate and replaced with SFM and cells 
were allowed to recover by incubation for 0-48h prior assaying for 
receptor-bound uPA activity or for uPA-binding sites on the cell 
surface. 
Proteins eluted from confluent HCT 116 cells (grown in 75cm2 
Corning flasks) by the above acid treatment were characterised by 
non-reducing SDS-PAGE, Western blotting and enzymography (as 
described below). After acid treatment, the eluates were 
centrifuged to remove any cell debris, dialysed against PBS at 40c 
for 16h with 3 changes of medium and concentrated 1 O-fo1d usmg 
Amicon YM-10 micro-concentrators, applied to 7.5 or 10% SDS-
PAGE gels, as indicated, under non-reducing conditions and either 
stained with Coomassie Brilliant Blue or transferred using a Bio-
Rad Transblot apparatus onto Hybond ECL (nitrocellulose, 
Amersham, UK). Monoclonal antibody against human uPA (MAb 
#394, American Diagnostica, Inc., USA) was used to probe the filter 
5 1 
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and the bound antibody was detected usmg the ECL 
immunoblotting kit (Amersham, UK) [Burnette 1981]. 
Gelatin enzymography was essentially performed according . to 
Heussen and Dowdle (1980). In detail, eluates prepared as above 
were separated on 10% non-reducing SDS-PAGE gels to which had 
been added 1 OJ..l.g/ml plasminogen and 0.1% gelatin as substrates. 
Lysis zones in the gelatin matrix in the SDS-PAGE gel were 
developed over a 90min incubation at 370 C in 1 OOmM 
glycine/NaOH pH 8.3, followed by staining with Amido black. 
Mobilities were compared to a human uP A standard (ie: a mixture 
of high (55kDa) & low (33kDa) Mr) and as well to Bio-Rad pre-
stained high Mr protein standards. 
2.2.8 1251-uPA binding assay 
The 125 I-uPA binding was performed according to Boyd and 
Brattain (1989). HCT116, KM12SM, LIM1215 and LS123 colon 
serum C-t1?1t'<~.iniflJ 
cancer cells were cultured in 24-well plates in.A!"etiiuV~ (ie: RPMI for 
HCT 116, LS123 and LIM1215 and DMEM for KM12SM) to -90% 
confluency. The cell monolayers were rinsed with SFM and then 
treated with acidic glycine buffer (50mM glycine/HCI pH 3.0, 0.1 M 
NaCl) at 40c for 3min followed by neutralisation with HEPES buffer 
(0.5M HEPES pH 7.5, O.lM NaCl) for lmin. To determine the density 
of unoccupied uPARs on the cell surface, the acid elution step was 
omitted. After another two washes with binding buffer (RPMI 0.1% 
BSA 20mM HEPES pH 7.4), the monolayer was incubated with a 
range of concentration of 1 2 5 I -uP A in binding buffer at room 
temperature for 45min. To determine the extent of nonspecific 
binding, a 50-fold excess of cold uPA was added into the 
incubation. Unbound uPA was removed by rinsing monolayers 
with binding buffer three times and the cells were then completely 
lysed in O.lM NaOH (370C, 2h). The radioactivity of the cell lysates 
was measured using a Packard Gamma Counter (AUTO-GAMMAR 
5650, Packard Instrument Company Inc., IL., USA.). The number of 
cells m identically treated wells was counted usmg a 
haemocytometer after trypsinisation. 
Scatchard analysis was used to calculate the dissociation 
constants and the average uPAR density [Segel 1975]. 
2.2.9 Cell viability 
The effect of experimental procedures on cell viability was 
estimated by trypan blue exclusion [Kaltenbach et al., 1958]. 
Adherent colon cancer cells were rinsed with SFM or acidic glycine 
buffer, washed twice using "fluorescence assay buffer" or "binding 
buffer" and then exposed to the fluorescence assay buffer 
containing plasminogen (2~g/ml) and VLL-AMC (0.1 mM) at 370c 
for 4h or to binding buffer containing unlabelled uP A (1 ~g/ml) at 
200c for 45min. After these treatments the cells were trypsinised 
and stained with 0.4% trypan blue prior to counting. Viability 
estimated by this method showed that ?;:.95% of cells from all 
treatments conducted here were viable. 
2.3 
2.3.1 
Results 
Development of a fluorimetric assay for the 
measurement of receptor-bound uPA activity 
Previously an indirect fluorescence assay has been used to 
observe the inhibitory effects of PAI-l and PAI-2 on receptor-
bound exogenously added uPA in U937 cells (ie: a human 
histiocytic lymphoma cell line) [Ellis et al., 1990]. Here, the utility 
of usmg an indirect fluorescence assay to measure the receptor-
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bound uPA activity on adherent human colon cancer cells has been 
determined. Experiments were mainly performed on the human 
colon cancer cell line, HCT 116 which has been reported to express 
endogenous receptor-bound uP A [Hollas et a!., 1991; Cohen et al., 
1991]. 
2. 3 .1.1 Standard fluorescence calibration curves for the 
cleavage of VLL-AMC by purified uPA 
Standard fluorescence calibration curves (Figure 2.1) for the 
cleavage of Val-Leu-Lys-4 aminomethyl coumarin (VLL-AMC) by 
purified uPA were obtained. When human plasminogen (2J..Lg/ml) 
and VLL-AMC (lOOmM) were incubated with human 55kDa active 
uPA (ADI uPA) in 50mM Tris-HCI O.lM NaCI, pH 8.0 at 370c, the 
release of 4AMC was both time and [uPA] dependent and was 
found to be linearly related to uP A final activity in the assay 
mixture over the range 25-500 miU/ml (ie: 5-l 00 miU/well) as 
shown in Figure 2.1. 
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2.3 .1. 2 Plasminogen activation by intact HCT116 cells 
To observe any plasminogen activation by intact HCT 116 cells, 
pre-rinsed HCT 116 cell were incubated with VLL-AMC (1 OO~M) 
and purified human plasminogen (2~g/ml) in the assay buffer at 
370c for 2h. The fluorescence intensity of 4AMC released from the 
VLL-AMC substrate was then measured in a Flow Laboratories 
"Titertek" Fluoroskan II plate-reader. Controls included measuring 
the fluorescence from VLL-AMC substrate alone, omitting cells, or 
omitting plasminogen and addition of TrasylolR (50 KIU/ml, final 
concentration). The fluorescence intensity m 
the wells with VLL-AMC substrate alone (Figure 2.2, column 1) 
66±1.1 was unchanged by a 2h incubation at 370c (data not 
shown) indicating that the spontaneous thermal 4AMC release was 
minimal. By contrast, high fluorescence intensity (1 053± 126) was 
observed when cells were incubated with plasminogen and VLL-
AMC (Figure 2.2, column 4 ). Cell free controls (Figure 2.2, column 
3, 117±3 .6) or wells that contained cells but not plasminogen 
(Figure 2.2, column 2 1 04±3 .1) were only slightly higher than that 
in the wells containing VLL-AMC alone. this result indicates that 
the marked 4AMC release seen in column 4 was due to the 
generation of plasmin from its inactive zymogen by the intact 
adherent cells. As has been reported, the activity of newly 
generated plasmin from plasminogen by intact cells was 
completely inhibited by TrasylolR (Figure 2.2, column 5). 
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Figure 2.2: 
cells 
Plasminogen activation by intact HCT116 
Confluent HCT116 cells (lxl06/we11, cultured on 24-well plate) were 
rinsed with assay buffer (50 mM Tris-HCl 0.1 M NaCl, pH 8.0) twice and then 
incubated at 370c for 2h with 100 f..LM H-D-Val-Leu-Lys-4 aminomethyl 
coumarin (VLL-AMC) and 2 f.lg/ml purified human plasminogen in 50 mM 
Tris-HCl pH 8.0, containing 0.1 M NaCl (500 f.ll) (column 4), or with VLL-AMC 
only (column 2), or with plasminogen, VLL-AMC and TrasylolR (50 KIU/ml, 
final concentration) (column 5). VLL-AMC alone (column 1) and 
plasminogen plus VLL-AMC (column 3) were used as controls. Fluorescence 
was measured as described in Fig 2.1. The data is represented as the mean±S. D. 
of triplicate samples. The experiment was repeated at least 3 times. 

The experiments were performed as described below. Adherent HCT116 cells 
(2xl05 cells/well, washed with serum free medium) on 96-well of plate were 
incubated in the Fluoro-assay buffer (50mM Tris-HCl pH 8.0, 0.1 M NaCl, 
160ul/well) at 370c for 4h and then chilled on ice. The supernatant was collected 
from some wells and spun to get rid off detached cells. 120ul of the supernatant 
was added into the blank wells preserved on the plate and incubated with VLL-
AMC (lOOuM) in the presence or absence plasminogen (2ug/ml). The total volume 
was corrected to 200ul!well with fresh assay buffer. VLL-AMC or VLL-AMC and 
plasminogen were also added to the wells containing both cells and the 
supernatant. The plate was returned back to 370c for 2h and the fluorescence 
intensity was measured. The fluorescence intensity of the wells containing VLL-
AMC and plasminogen only were taken as zero. The result was shown in Table A. 
Without plasminogen, a low fluorescence intensity was obtained in both 
supernatant only wells and cells plus supernatant wells that might be due to cell 
surface associated plasminogen or plasmin from culture medium. In the presence 
of plasminogen, a slightly higher fluorescence intensity was observed in wells 
containing the supernatant compared to the control wells (a) indicating the 
presence of plasminogen activator, but it was much lower than that of the wells 
containing both cells and the supernatant (less than 5%). The result suggested that 
during the Fluoro-assay, the major part of plasmin activity generated on cell 
surface (>95%), uPA in the supernatant did not contribute significantly to the 
development of fluorescence intensity. 
Table A, uP A activity in the supernatant and on cell surface 
Fluorescence intensity 
- Plasminogen 
Supernatant 3.8 ± 1. 78a 
Cells & supernatant 2 2. 7 ± 1. 7 6 c 
+ Plasminogen 
11.6 ± 0.78b 
722 ± 68.2d 
The data were the mean±S.D. of triplicate samples. P<0.05 when a vs b, c, & d; b vs 
c & d; and c vs d. n=2 
1000 
>-I-
-(/) 
z 
w 750 I-
z 
w 
u 
z 500 
w 
u 
(/) 
w 
0.::: 250 0 
:::> 
_J 
l.L 
0 
1 2 3 4 5 
The experiments were performed as described below. Adherent HCT116 cells 
(2xi05 cells/well, washed with serum free medium) on 96-well of plate were 
incubated in the Fluoro-assay buffer (SOmM Tris-HCl pH 8.0, 0.1 M NaCl, 
160ul!well) at 370c for 4h and then chilled on ice. The supernatant was collected 
from some wells and spun to get rid off detached cells. 120ul of the supernatant 
was added into the blank wells preserved on the plate and incubated with VLL-
AMC (IOOuM) in the presence or absence plasminogen (2ug/ml). The total volume 
was corrected to 200ul!well with fresh assay buffer. VLL-AMC or VLL-AMC and 
plasminogen were also added to the wells containing both cells and the 
supernatant. The plate was returned back to 370c for 2h and the fluorescence 
intensity was measured. The fluorescence intensity of the wells containing VLL-
AMC and plasminogen only were taken as zero. The result was shown in Table A. 
Without plasminogen, a low fluorescence intensity was obtained in both 
supernatant only wells and cells plus supernatant wells that might be due to cell 
surface assodated plasminogen or plasmin from culture medium. In the presence 
of plasminogen, a slightly higher fluorescence intensity was observed in wells 
containing the supernatant compared to the control wells (a) indicating the 
presence of plasminogen activator, but it was much lower than that of the wells 
containing both cells and the supernatant (less than 5%). The result suggested that 
during the Fluoro-assay, the major part of plasmin activity generated on cell 
surface (>95%), uPA in the supernatant did not contribute significantly to the 
development of fluorescence intensity. 
Table A, uP A activity in the supematant and on cell surface 
Fluorescence intensity 
- Plasminogen + Plasminogen 
Supernatant 3.8 ± 1.78a 11.6 ± 0.78b 
Cells & supernatant 22.7 ± 1.76C 722 ± 68.2d 
The data were the mean±S.D. of triplicate samples. P<O.OS when a vs b, c, & d; b vs 
c & d; and c vs d. n=2 
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2. 3 .1. 3 Effect of tranexamic acid on plasminogen cleavage 
by intact colon cancer cells 
To determine whether the activation of plasminogen by intact 
colon cancer cells occurs on the cell surface or in the solution 
phase, tranexamic acid (TA) (a lysine-like analogue) was used to 
inhibit plasminogen binding to cell surface plasminogen receptors 
[Stephens et al., 1989] using the system described in sections 2.3.1 
and 2.3.2. 
Confluent HCT116 cells (2xi05 /well in 96 well plates) or 
purified soluble uPA (55kDa, tcuPA, 20miU/well) were incubated 
with 2j..ig/ml plasminogen, VLL-AMC substrate and T A ranging 
from 0-lOOj..tM in 50mM Tris-HCl O.lM NaCl, pH 8.0 at 370c for 4h. 
The presence of T A had no effect on the activation of purified 
plasminogen by soluble uP A (Figure 2.3, open circles), while T A 
strongly inhibited (>95%) the activation of plasminogen by 
adherent HCT 116 cells (Figure 2.3, open triangles) at 
concentrations as low as 25j..tM. These results indicated that the 
activation of plasminogen by intact cells proceeds on the cell 
surface through the action of a surface-associated plasminogen 
< P~9"") · 
activatorA._ In addition, experiments where medium was removed 
and assayed separate to the cells indicated that uPA in the medium 
(ie: secreted by cells during the assay) did not contribute 
significantly to the development of fluorescence intensityC f~ a). 
Figure 2.3: Comparison between the effects of 
tranexamic acid on plasminogen cleavage by purified uPA 
and by intact HCT116 cells 
Confluent HCT116 cells (2x105/we11, cultured on 96-well plates) 
(triangles) or standard uPA (55 kD, two chain, 20 miU/well) (circles) were 
incubated with plasminogen (2 J..lg/ml), VLL-AMC (100 J..lM) and tranexamic 
acid in 50 mM Tris-HCl 0.1 M NaCl, pH 8.0 at 370 C for 4h. The assay reagents 
were then transferred to black microtitre plates which contained 10 J..ll of 
TrasylolR (10 KIU) to stop further cleavage of VLL-AMC. Fluorescence was 
measured as described in Fig 2.1. The data is represented as the mean±S.D. of 
triplicate samples. The experiment was repeated at least 3 times. 
Using binding assays, tranexamic acid had been found to inhibit plasminogen, 
but not uPA, binding to HCT116 cells (data not shown). Tranexamic acid had no 
direct effect on plasmin and uP A activity when they were in solution and small 
peptide substrate were used to measure plasmin activity (Fig. 2.3). Therefore, the 
effect of tranexamic acid on the plasminogen activation by intact HCT116 cells was 
due to inhibiting plasminogen binding to HCT116 cells. 
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2.3.1.4 Effects of anti-uPA (MAb #394) and anti-tPA 
(MAb #387) antibodies on plasminogen cleavage 
by adherent HCT116 cells 
To examine which type of PA (uPA, tPA or both) contributed 
to plasminogen activation by HCT 116 cells, monoclonal antibodies 
(MAb), #394 [directed against all forms (ie: scuPA, 55kDa tcuPA & 
33kDa tcuPA) of human uPA] or #387 (specific for human tPA) 
were employed. Confluent HCT 116 cells ( 1 x 1 o6 /well) were 
incubated with plasminogen (2 jlg/ml), VLL-AMC ( 1 OOj.!M) in the 
presence of MAb #394 or MAb #387 (0-lOj.!g/ml) in 50mM Tris-
HCl , O.lM NaCl, pH 8.0 at 370c for 2h. Up to 10 jlg/ml, MAb #387, 
anti-tPA IgG failed to produce a measurable inhibition, indicating 
that tPA did not contribute to the plasminogen activation 
associated with intact HCT 116 cells (Figure 2.4, open squares). In 
contrast, MAb # 394 inhibited plasmin formation in a dose-
dependent fashion (with a ISO% at a concentration of 0.75jlg/ml 
MAb #394) (Figure 2.4, open circles). These results indicate that 
receptor-bound endogenous uP A on HCT 116 cell surface is solely 
responsible for the observed flourescence intensity generated by 
cells in the presence of plasminogen. These results also indicate 
that MAb # 394 inhibits uP A-driven plasmin formation in this 
particular assay despite the fact that it still reacts with preformed 
uPA:PAI-2 complexes (McPhun & Baker, personal communication). 
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Figure 2.4: 
and MAb#387 
cells 
Effects of monoclonal antibodies, MAb#394 
on plasminogen activation by intact HCT116 
Confluent HCT116 cells (lx106/we11) were incubated with plasminogen 
(2 Jlg/ml), VLL-AMC (100 JlM) and MAb#394 (against all forms of uPA) 
(circles) or MAb#387 (against t-PA) (squares) in 50 mM Tris-HCI 0.1 M NaCl, 
pH 8.0 at 370 C for 2h. Then the assay reagents were transferred to black 
microtitre plates which contained 10 Jll of TrasylolR (10 KIU) to stop further 
cleavage of VLL-AMC. Fluorescence was measured as described in Fig 2.1. The 
data are expressed as the mean±S.D. of triplicate samples. The experiment was 
repeated at least 3 times. 
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2. 3 .1. 5 Influence of plasminogen concentration on the 
indirect uPA activity assay 
When HCT 116 cells ( 1 X 1 o6 /well) were incubated with 
increasing initial concentrations of purified human plasminogen 
(0-25J..Lg/ml) in the indirect VLL-AMC assay (Figure 2.5), an initial 
rapid dose-dependent rise in fluorescence intensity (~2 J..Lg/ml) was 
observed with a less sharp rise occurring at levels L2 J..Lg I m 1 
plasminogen. Subsequent experiments routinely employed 2 J..Lg/ml 
as the concentration of plasminogen added to cell surface uPA 
assays. 
2.3.1.6 Sensitivity of the receptor-bound uPA activity 
assay to cell number 
Confluent HCT 116 cells cultured in a 75cm2 flasks were 
treated with 0.25% trypsin at 370c for 2min to obtain single cell 
suspensions and washed with two volumes of serum-containing 
medium to inhibit the activity of trypsin. After another two 
washes with assay buffer (50mM Tris-HCI O.lM NaCl, pH 8.0), cells 
were resuspended m lml of assay buffer and cell density was 
determined with a haemocytometer. Increasing cell numbers 
(0.5xi05 to 2.0xi05 cells) were incubated with human 
plasminogen (2J..Lg/ml) and VLL-AMC (1 OOJ.!M) in the assay buffer 
at 370c for 4h. Fluorescence intensity increased with increasing 
cell numbers (Figure 2.6) and reproducible receptor-bound uPA 
activities were detectable with as few as 0.5x 1 o5 cells added. 
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Figure 2.6: Sensitivity of the indirect receptor- bound 
uPA activity assay 
Confluent HCT116 cells cultured in a 75 cm2 flask were treated with 
0.25% trypsin at 370c for 2 min to obtain a single cell suspension, and washed 
with two volumes of serum-containing medium to inhibit the activity of 
trypsin. After another two washes with assay buffer (50 mM Tris-HCI 0.1 M 
NaCI, pH 8.0), the cells were resuspended in 1 ml of assay buffer, and cell 
density was determined using a haemocytometer. 0.5x 1 o5 to 2.0x 1 o5 cells were 
incubated with human plasminogen (2 JJ.g/ml) and VLL-AMC (100 J.!M) in the 
assay buffer at 370 C for 4h. The fluorimetric assay was stopped by the 
addition of 10 J.!l of TrasylolR (10 KIU) and fluorescence was measured as 
described in Fig 2.1. The data are expressed as the mean±S.D. of triplicate 
samples. The experiment was repeated at least 3 times. 
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examme its , the indirect receptor-
activity assay was used to measure receptor-bound uPA 
on cells which were then supplemented 
exogenously ded 55 a uP . Confluent CT116 cells 
( 1 X 1 06/well) were exposed to acidic glycine buffer (as 
or S at 4 Oc 3min 
0.5 HE PES 7 containing 0.1 
s s were )m 
BS s or 
to remove 
n 1) 
(1 
370 7 
at erent 116 cells ss 35 13 
uP 106 cells (Figure 2 , column 1) and that exposure to acidic 
glycine buffer resulted in a mean 58% loss of receptor-bound uPA 
activity (147±10 miU/106 cells) (Figure 2.7, column 3). Pre-
incubation of PBS-rinsed HCT 116 cells (Figure 2.7, column 2) with 
exogenous uP A increased receptor-bound uP A activity by 21% 
( 4 2 9± 15 miU 11 o6 cells), indicating the binding of additional 
exogenous uP A to "unoccupied" cell surface uP AR. Suprisingly, 
when acid-rinsed HCT 116 cells (Figure 2. 7, column 4 ), were 
subsequently incubated with exogenous uPA there was a very 
substantial mcrease in receptor-bound uPA activity (800±2 6 
miU 11 o6 cells). This result represents a 7 .5-fold increase 
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116 cell surface uPARs are already 
by non-activatable ligands (eg: inactive 
PAI complexes). uPAR can be " 
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exogenous results higher receptor-bound 
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.3,2,2 on 1251-u -b 1 6 s 
125 
16 s were 
125 I s 
After 125 I- were 
lysed 0.1 NaO and radi ity of the sates 
measured. Figure 2.8 indicates that the amount of 1251-uPA bound 
was higher at all concentrations of added radioactive ligand for 
acid-treated HCT116 cells (Figure 2.8, filled circles) compared to 
untreated cells (Figure 2.8, open circles). At the highest 
concentration of added ligand examined (240 11 g/ml), the amount 
of 125 1-uPA bound to acid-treated cells was 4-fold higher than 
that bound to PBS-washed cells. This result most confirms that 
additional endogenous ligands are eluted from cell surface by acid-
66 
treatment, m agreement with observations made previously with 
the indirect receptor-bound uP A activity assay. 
2.3 .2.3 Analysis of proteins acid-eluted from HCT116 
cells 
To confirm that uPA had been acid eluted from cell surfaces 
by the acid elution procedure, eluate medium was neutralised, 
centrifuged, dialysed and concentrated and analysed by 10% non-
reducing SDS-PAGE as described in section 2.2. 7. The most 
prominent species eluted from HCT 116 cells had a molecular 
weight of 55kDa (Figure 2.9, track B) which corresponds to that of 
high molecular weight human uPA. In addition to the 55kDa band, 
other less intense stained protein bands were acid eluted from 
HCT116 cells, including bands at 50 and 39 kDa and a series of 5 
faint bands in the range 74-82 kDa (track B). 
Western blotting studies (Figure 2.1 0) on these acid eluates, 
usmg a commercial MAb immunoreactive against human uP A 
(MAb #394) indicated that the most prominent species at Mr of 55 
kDa was immunoreactive with anti-uPA MAbs. In addition, other 
less intense but higher molecular weight bands were found on 
Western blots, with Mr that corresponded to 85, 95 and >220 kDa 
respectively. The presence of these bands provides strong 
additional evidence that other uPA-ligand complexes (eg: uPA:PAI 
complexes or uPA-uPA binding protein complexes) are eluted from 
uP ARs in addition to authentic 55kDa scuPA or tcuP A. 
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Figure 2. 7: Effects of acid-elution and the addition of 
exogenous uPA on HCT116 cell surface uPA activity 
Confluent HCT116 cells (lx106/well) were exposed to acidic glycine 
buffer (50 mM Glycine/HCl pH 3.0, O.lM NaCI) (columns 3 & 4) or PBS 
(columns 1 & 2) at 40c for 3 min and then neutralised with 1/5 volume of 0.5 
M HEPES pH 7.5 containing 0.1 M NaCI. After washing with serum-free 
medium, the cells were incubated with 55 kD tc-uPA (10 IU/ml) in binding 
buffer (RPMI 0.1% BSA 20 mM HEPES pH 7.4) (columns 2 & 4) or binding 
buffer alone (columns 1 & 3) at 4 0 C for 30 min and then rinsed with the 
binding buffer twice to remove unbound uPA. These cells were then 
incubated with human plasminogen (2 J..lg/ml) and VLL-AMC (100 JlM) in 50 
mM Tris-HCI 0.1 M NaCl, pH 8.0 at 370c for 2h, and the fluorescence intensity 
of released 4AMC was measured using excitation 355 nm and emission 460 nm 
in a Flow Laboratories "Titertek" Fluoroskan II plate-reader. The 
fluorescence intensity was calibrated to uPA activity by the standard uPA 
curve performed in the same time. The data are expressed as the mean±S.E. of 
five individual experiments. 
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Figure 2.8: Effect of acid elution on radioactive uPA 
binding to HCT116 cells 
Confluent HCT116 cells (0.9-1.2x106 /well) were rinsed with serum free 
medium, and then treated with acidic glycine buffer (50 mM Glycine/HCI pH 
3.0, 0.1 M NaCI) (filled circles) or serum-free medium (open circles) at 40c for 
3 min followed by neutralisation with HEPES buffer (0.5 M HEPES pH 7.5, O.lM 
NaCl). After another two washes with binding buffer (RPMI, 0.1% BSA, 20 mM 
HEPES, pH 7.4 ), the cells were incubated with increasing concentrations of 
1251-uPA in binding buffer at room temperature for 45 min. Unbound uPA 
was removed by rinsing the monolayers with binding buffer three times. 
The cells were lysed in 0.1 M NaOH (370C, 2h). Radioactivity of the cell lysates 
were measured on Gamma Counter (AUTO-GAMMAR 5650, Packard Instrument 
Company Inc., IL., USA.). The cell number in identical wells was counted on 
haemocytometer after trypsinization. The data is represented as the 
mean±S.D. of duplicate samples. The experiment was repeated at least 3 times. 
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by acid 
2.9: SDS-PAGE 
elution 
of cell-surface proteins released 
Confluent HCT116 cells (1.5x107) in 75 cm2 flasks were treated with 4 
ml of acidic glycine buffer (50 mM Glycine/HCI pH 3.0, 0.1 M NaCl) at 40c for 
3 min. The eluate was neutralised, centrifuged, dialysed and concentrated as 
in "Acid elution procedure" and then analysed by 10% non-reducing SDS-
PAGE with Coomassie blue staining (track B). Track A is the Bio-Rad 
standards. Arrow indicates the mobility of high Mr uPA (55 kD) standard. 
31.0~ 
Figure Western cellm~mrface pro ns 
tion 
Acid eluates from confluent HCT116 cells were separated on 7.5% non-
reducing SDS-PAGE gels, transferred using a Bio-Rad Transblot 
onto bond ECL trocellulose, Amersham, UK) and probed with 
monoclonal antibody against human uPA (MAh #394, American Diagnostica, 
Inc., USA) and detected using the ECL immunoblotting kit (Amersham, UK). 
In controls, mouse IgG against human PAI-2 or mouse IgG against human t-
PA were used as the antibodies shown). Star indicates the 
molecular uPA 
1 
After neutralisation and concentration of acid eluates, the 
molecular weight of uPA activity was determined usmg 
plasminogen-dependent gelatin enzymography on 10% SDS-PAGE 
gels. Figure 2.11 indicates that acid eluates contained a 
plasminogen activator which exhibited a strong band of lysis (track 
A) that co-migrated with standard 55kDa human uPA (track B). In 
addition, a less intense band of lysis was seen at -105 kDa and a 
faint lytic "smear" was observed between the 105 kDa and the 
55kDa maJor lytic bands. Lysis bands did not appear if 
plasminogen was left out of the gel matrix or if the gels were 
soaked in amiloride indicating that the lysis zones were dependant 
upon uPA (data not shown). In contrast to the results obtained 
after elution with acid, treatment with PBS did not result in the 
release of significant active lytic material. 
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Figure 2.11: Enzymography of cell-surface proteins 
released by acid elution 
Confluent HCT116 cells (1.5x107) in 75 cm2 flasks were treated with 4 
ml of acidic glycine buffer (50 mM Glycine/HCl pH 3.0, 0.1 M NaCl) (track A) 
or PBS (not shown) at 40c for 3 min and then neutralised with 1 ml of HEPES 
buffer (0.5 M HEPES pH 7.5 containing 0.1 M NaCl). The eluates were 
centrifuged to remove any cell debris, dialysed against PBS at 40c for 16h 
with 3 changes of medium, concentrated 10-fold using Amicon YM-10 micro-
concentrators, and separated on 10% non-reducing SDS-PAGE gels 
contammg 10 ll g/ml plasminogen and 0.1% gelatin. Lysis zones were 
developed over a 90 min incubation at 370c in 100 mM glycine/NaOH pH 8.3, 
followed by staining with Amido black. Human uPA standard (mixture of 
high & low Mr) (track B) and Bio-Rad pre-stained high Mr standards (track 
C) are shown. Star indicates the mobility of high molecular weight uPA (55 
kD). 
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Table 2.1 Receptor-bound and soluble uPA activity in 
cultured colon cancer cell lines 
Cell lines 
HCT 116 
KM12SM 
LIM1215 
LS123 
Receptor- bound uP A 
miU/t06cells 
354 ± 3sa 
137 ± 29b 
234 ± 38C 
290 ± 30d 
uPA in medium 
miU/t06cells/24h 
268 ± 34a I 
91 ± 14 b' 
804 ± SIC' 
ND 
Cell surface and supernatant uPA activity was measured by an indirect 
fluorescence assay (see Materials and methods in Chapter 2 for detail). These 
data represents the mean and SD of five individual experiments for each cell 
line. The experiments were conducted using at least duplicate samples. uPA 
activity in LS123 cultured medium was undetectable by this assay. P<0.01 a 
vs b, c, and d or b vs c and d by t-test; P<0.05 c vs d by t-test; P<O.Ol a' vs b' and 
c' or b' vs c' by t-test. 
2.3.3.2 Cell surface uPAR 
Functional cell surface uP AR content m these colon cancer cell 
lines was measured using the 12 51-uP A binding assay. To 
approximate "total uP A-binding sites available", cells were 
pretreated with acidic glycine buffer to remove as much 
endogenous uPA and uPAR:uPA ligands as possible and as 
described earlier. "Unoccupied" cell surface uPAR content was 
measured identically except that the acid elution step was omitted. 
Specific binding of 125 I-uP A was calculated as the difference of the 
binding between cells that were not exposed to unlabelled 
exogenous uPA and those treated with 50-fold excess "cold" 
(unlabelled) uPA. 
Figure 2.12 indicates specific binding of 125 1-uPA (Figure 
2.12, open triangles) on acid-eluted HCT 116 cells. These data were 
obtained by subtracting the nonspecific binding (ie: cells treated 
with 50-fold "cold" uPA; Figure 2.12, filled triangles) from the total 
125 1-uPA binding (Figure 2.12, filled squares). 
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Figure 2.12: Specific binding of radioactive uPA to 
HCT116 cells 
Confluent HCT116 cells (0.9-1.2x106/well) were pretreated with acidic 
glycine buffer to remove endogenous uPA as described in "Acid elution 
procedure". After two further washes with binding buffer (RPMI, 0.1% BSA, 
20 mM HEPES, pH 7.4), the cells were incubated with 0-1,000 ng/ml of 1251-
uPA in the presence (filled triangles) or absence (filled squares) of 50-fold 
unlabelled uPA at room temperature for 45 min. Unbound radioactivity was 
removed by washing the cells with the binding buffer three times. The cells 
were lysed in 0.1 M NaOH (370c, 2h). Radioactivity of the cell lysates were 
measured as described in Fig 2.8. The specific binding of 1251-uPA (open 
triangles) in acid-eluted HCT116 cells was obtained by subtracting the 
nonspecific binding (filled triangles) from the actual binding (filled 
squares). The data is represented as the mean of duplicate samples. 
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Figure 2.13: Scatchard analysis of radioactive uPA 
binding to HCT116 cells 
The binding of radioactive uPA to acid-eluted HCT116 cells (open 
circles) and untreated HCT116 cells (filled circles) was performed as 
described in Fig 2.12. Scatchard analysis was performed on the binding data 
obtained. 
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Table 2.2 uPAR capacity of cultured colon cancer cell lines 
With acid elution Without acid elution 
Cell lines binding sites/cell Kd (nM) binding sites/cell Kd (nM) 
HCT 116 53,565 ± 4263 8 1.17±0.178' 15,200 ± 115 0 e 1.18 ± 0. 0 6 
KM12SM 20,227 ± 600b 1.31 ± 0.15 b' 13,785 ± 421 1.39 ± 0. 0 9 
LIM1215 26,628 ± 1515C 1.25 ± 0 • 11 C I 11,227 ± 813 0.90 ± 0. 2 5 
LS 123 36,625 ± 875d 1.20 ± 0.10 d' 
The uPAR capacity of cultured colon cancer cell lines was determin~d by a 1251-uPA binding assay (see Materials and 
methods in Chapter 2 for detail). The data represent the mean and SD from at least 3 individual experiments. In every 
experiment duplicated samples were used for each 1251-uPA concentration. The uPAR capacity on uneluted LS123 was 
not measured. P<O.Ol a vs b, c, and d by t-test; P<0.05 b vs c and d or c vs d by t-test; P<O.Ol a vs e by t-test. P>0.05 a' vs b', 
c' and d' or b' vs c' and d' by t-test. 
2. 3. 3. 3 Relationship 
endogenous 
between uPAR capacity and 
receptor-bound uPA activity 
The relationship between uPAR capacity (from section 2.3 .8.2) 
and endogenous receptor-bound uP A activity (from section 2.3.8.1) 
was examined using linear regression on the data obtained in these 
sections (Figure 2.14 ). There is a good correlation (r2 = 0. 9 0) 
between total uPAR capacity (1251-uPA-binding) and endogenous 
receptor-bound uPA activity and the data clearly indicate that 
HCT 116 expresses the highest level of available uP AR sites as well 
as the highest level of endogenous cell surface uP A activity. This 
analysis also shows that HCT 116 and KM 12SM have a slightly 
lower proportion of total uPARs occupied with either scuPA or 
tcuP A (below the regression line) than LIM 1215 and LS 123 (above 
the regression line). Since HCT 116 express the highest levels of 
available uPAR sites and endogenous cell surface uPA activity, this 
cell line was chosen for all subsequent studies. 
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Figure 2.14: Regression analysis on the relationship of 
uPAR capacity and endogenous receptor-bound uPA 
activity in cultured colon cancer cell lines 
The uPAR binding capacity of cultured colon cancer cell lines (Table 
2.2) was plotted against the endogenous receptor-bound uPA activity (Table 
2.1) and the relationship examined by regression analysis. The correlation 
index (r2) is shown. 
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uP A tumour sue or produced by cultured tumour cells is 
predominantly in its scuP A form [Sim et al., 1988, Stephens et al., 
1989]. The majority (>90%) of receptor-bound uPA on HCT116 cell 
surface was found to be in the zymogen form [Baker et al., 1992]. 
On the cell surface, receptor-bound scuPA can be proteolytically 
converted to an active two-chain molecule by receptor-bound 
plasmin [Stephens et al., 1989; Pollanen et al., 1991]. In the 
indirect uP A activity assay, receptor- bound scuP A will 
automatically be converted to active uPA by plasmin generated on 
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addition to uPA being present on uPARs, there may also be some 
inactive uPA-containing ligands which are eluted from the cell 
surface by the acid elution procedure. The faint band of lysis at 
1 05kDa on gelatin enzymography has a similar Mr to that of the 
uP A/P AI -1 complex observed by Cohen et al. (1991) using the 
same method on the same cell lines [Cohen et al. 1991 ]. To test this, 
Western blotting analysis on acid-eluates usmg anti-PAI-l 
antibody has been tried, but results were inconclusive (data not 
(P83a) 
shownl'( Another possible explanation is that acid elution favours 
dissociation of uP A- P AI complexes bound to other receptors such 
as serpin receptors (eg: a2macroglobulin receptors (called a2MR or 
83 
LRP), so that the net uPA activity reflects receptor-bound uPA 
activity as well as that possibly complexed to PAis. In the presence 
of excess exogenous uPA however, dissociated PAI-l binds in 
soluble phase to the vast excess of uPA so that the receptors 
previously occupied by uPA-PAI-1 complexes become occupied by 
exogenous uP A. 
Endogenous receptor-bound uPA activity and cell surface 
uPAR capacity were compared in 4 colon cancer cell lines. Among 
the cell lines, HCT 116 expressed the most uP A-binding sites and 
highest endogenous receptor-bound uP A activity, KM 12S M 
expressed the least uPA-binding sites and the lowest endogenous 
receptor-bound uP A activity. There was a good correlation 
(r2=0.90) between cell surface uPA-binding sites and endogenous 
receptor-bound uPA activity in these cell lines. But receptor-bound 
uP A activity did not correspond in any way to the uP A activity 
found m cell conditioned medium (ie: soluble uPA). The role of 
uPAR in regulating receptor-bound uPA activity was made clearer 
when the expressiOn of uP AR was separated from the expression of 
uPA: in a cell line that produces obviously high levels of uPA but 
few uPARs (such as LIM1215), excess uPA was observed m 
conditioned medium rather than on the cell surface. In contrast, in 
cell line that expressed low uPA activity but high uPAR expression 
(eg: LS 123), the majority of uP A is found in receptor-bound form. 
The role of uPAR in determining the levels of receptor-bound 
uPA activity and the role of receptor-bound uPA in experimental 
colon cancer invasion and metastasis will be examined in following 
chapters. 
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3.1 Introduction 
shed in Chapter 2, receptor-bound endogenous 
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• uPAR, uPA and PAI gene expresswn and mRNA stability 
• rate of secretion of uP A and cell content of cell surface uP AR 
and PAis 
• binding and dissociation constants of scuP A to cell surface 
uPARs 
• the rate of activation of receptor-bound scuPA to tcuPA by 
plasmin or other as yet to be defined proteases 
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• expression of PAis at an appropriate cellular location (eg: the 
leading edge . . or mvastve front) and the rate constant for 
inhibition of receptor-bound tcuPA by PAis 
• the rates of internalization and degradation of uP A: P AI 
complexes 
• the rates of re-expresswn (recycling) or de novo synthesis of 
uP AR to the cell surface 
The effectiveness of the physiological PA inhibitors PAI-l and 
PAI-2 to inhibit receptor-bound cellular uPA activity is currently a 
matter of some debate. According to Kirchheimer and Remold 
(1989), the activity of uPA bound to human blood monocytes was 
inhibited only at high concentrations of PAI-2 and was completely 
refractory to inhibition by PAI-l. In another contrasting study, the 
activity of exogenous uPA bound to U937 cells was efficiently 
inhibited by both PAI-l and PAI-2, but with a lower ( -40% 
decrease) association rate constant in both cases (Ka = 4.5xi06 M-1 
S -1 for PAI-l and Ka = 3.3xl o5 M-1 s-1 for PAI-2) compared to 
the inhibition of uPA in solution where the respective 
association rate constants were Ka = 7.9xi06 M-1 s-1 for PAI-l 
and Ka = 5.3xi05 M-1 s-1 for PAI-2 [Ellis et al., 1990]. 
Recombinant P AI-2 inhibits radiolabelled ECM degradation 
mediated by a range of colon cancer cells but higher concentrations 
of PAI-2 ( -15-fold higher) were required compared to those 
needed to inhibit a comparable amount of soluble tcuPA [Baker e t 
al., 1990]. Overall these data suggest that the high Mr protein PAIs 
(ie: PAI-l and PAI-2) are less quick and less efficient inhibitors of 
receptor-bound tcuPA than of soluble tcuPA. 
In addition to the physiological inhibitors (PAI-l and PAI-2), 
a number of chemical inhibitors of uPA such as amiloride and Glu-
Gly-Arg chloromethyl ketone (GGA-CMK) have been employed. 
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Amiloride is a diuretic drug which inhibits soluble uPA activity 
with a Ki = 111M [Vassalli and Belin, 1987]. GGA-CMK, a reagent 
corresponding to the C-terminal sequence generated -in 
plasminogen upon activation by uPA, is a selective irreversible 
inhibitor of uPA with a Ki = l.811M [Kettner and Shaw, 1979]. The 
effects of both of these chemical inhibitors on cell surface receptor-
bound uPA activity and on ECM degradation initiated by cancer 
cells have not previously been determined. 
The aim of this chapter was to examine and compare the 
effects of the uPA inhibitors (PAI-2, amiloride and GGA-CMK) on 
colon cancer cell surface receptor-bound uPA activity and 
subsequently on ECM degradation initiated by receptor-bound 
endogenous uPA. 
3. 2 Materials & Methods 
3.2.1 Materials 
Recombinant human PAI-2 was kindly supplied at 3mg/ml in 
50mM glycine, pH 9.0 with a molecular weight of 47kDa and 
specific activity of 68,040 IU/mg soluble protein by Biotech 
Australia, Roseville, Australia. Amiloride and endothelial growth 
supplement were obtained from Sigma Chern. Co., ST. Louis, USA. 
Glu-Gly-Arg-chloromethyl ketone was purchased from Calbiochem. 
Sydney, Australia. [3 H)-serine was purchased from Amersham, 
Amersham, United Kingdom. Other reagents used in this study 
have already described in Chapter 2. 
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3.2.4 Preparation of [3 H]-serine labelled subendothelial 
ECMs 
Endothelial cells derived from human umbilical veins were 
kindly supplied at low passage number (passage 3 - 4) by Ms 
Susan Maynes (Division of Cell Biology, John Curtin School of 
Medical Research, ANU, Australia) and were maintained in Medium 
199 containing 20% FCS, 2mM heparin, 2mM glutamine, 50j.lg/ml 
gentamycin and 50j...tg/ml endothelial growth supplement. The cells 
were seeded into Nunc flasks coated overnight with 0.1% gelatin 
and grown at 370c in 5% C02 until confluent. 
Endothelial cells were treated with trypsin-Versene buffer, 
seeded onto gelatin-coated 24-well plates and grown to confluency. 
Fresh medium added daily contained 5 f.lCi/ml [3H]-serine and was 
also supplemented with 20f.lg/ml fresh ascorbate daily. Labelling 
medium was replaced every 3 days. After isotopic labelling, the 
endothelial cell monolayer was washed with PBS and cells were 
lysed by the addition of 30 mM NH4 OH for 30min at room 
temperature, rinsed gently with PBS and sterile H2 0 followed by 
70% ethanol and then air-dried. This procedure left a thin intact 
ECM structure coating the bottom of the wells which resembled 
basement membrane as seen under transmission electron 
microscopy [Baker et al., 1990]. Plates not used immediately were 
stored at room temperature under sterile conditions until required. 
3. 2. 5 ECM degradation by colon cancer cells 
HCT 116 cells or KM 12SM (0.5x I 06 cells/well) were seeded on 
pre-washed [3H]-serine labelled ECM in 0.5 ml RPMI containing 2% 
FCS for 24h to form a near-confluent monolayer. After adherence, 
the cultured medium was replaced with SFM supplemented withe 
20 f.lg/ml plasminogen and the cultures were continued at 370 C 
from 2 - 8h. After removing and storing the plasminogen-
containing medium, wells were rinsed twice with PBS and then 
incubated with 0.3M NaOH to recover any additional [3 H]- serine 
labelled material left within the ECM remaining after degradation. 
Aliquots of the culture media and the alkaline ECM lysates were 
counted to determine the levels of [3H]-serine in the samples. The 
data were expressed as the percentage of the total label which was 
equivalent to the sum of cpm obtained from [3H]-serine released 
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Tl , amiloride (0-800 ~-tM) or GGA-CMK (0-88 11 were 
added to the plasminogen-containing medium immediately after 
116 cells had formed a near-confluent adherent monolayer 
on the [3 -serine radiolabelled ECM. 
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uPA. For example, O% for purified uPA (at 200 miU/200~-tl well) 
was attained at 5. 7Tl M P AI -2. In contrast, receptor- bound 
endogenous uP A on 2x 1 o5 HCT 116 cells ( ~354 miU/ml or 
71 miU/well) had an I5 0% = 22.711 M PAI-2. This result is m 
agreement with the observation that inhibition of adherent cell-
mediated ECM degradation was at least partially shielded from 
inhibition by soluble recombinant human PAI-2 [Baker et al., 
1990]. 
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Figure 3.1: A comparison of the inhibition of soluble or 
HCT116 cell surface uPA activity by PAI-2 
Confluent HCT116 cells (filled circles) (2x to5 /well) or purified uP A 
(open circles) (200 miU/well) were incubated at 370c for 2h with 100 11M 
VLL-AMC, 2 Jlg/ml purified human plasminogen, and increasing 
concentrations of PAI-2 in 50 mM Tris-HCl pH· 8.0, containing 0.1 M NaCI (200 
Jll). Fluorescence of free 4AMC released from VLL-AMC was measured using 
excitation 355 nm and emission 460 nm in a Flow Laboratories "Titertek" 
Fluoroskan II plate-reader and was calculated to uPA activity according to 
the internal uPA standard curve. The data represent the mean of triplicate 
samples. The experiment was repeated at least 3 times. 
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dosage-dependent fashion. these studies the 0% on 
required to inhibit endogenous uP A activity on HCT 116 cells was 
77!-lM, a result similar to the Iso% (ie: 82!-lM) for lOOmiU solu 
purified uPA. These results indicate that unlike PAJ-2, the low Mr 
uPA inhibitor amiloride inhibits receptor-bound uPA acti as 
efficiently as it inhibits purified soluble uPA. 
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Figure 3.3: Inhibition of receptor-bound uPA activity 
by amiloride 
Confluent HCT 116 cells (filled circles) (2x 1 o5twe11) or purified uP A 
(open circles) (100 miU/well) were incubated at 370c for 2h with 100 J.!M 
VLL-AMC, 2 J..lg/ml purified human plasminogen, and increasing 
concentrations of amiloride in 50 mM Tris-HCI pH 8.0, containing 0.1 M NaCl 
(200 J.!l). Fluorescence was measured and calculated as uPA activity according 
to the internal uPA standard curve. The data represent the mean of triplicate 
samples. The experiment was repeated at least 3 times. 
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3.3.1.3 GGA-CMK 
Peptide chloromethyl ketones represent a class of synthetic 
proteinase in hi bi tors that in hi bit serine proteinases via 
irreversible affinity labelling of their active sites. They bind to the 
active centre of the enzymes resulting in the alkylation of the 
active-centre histidine residue. Compared to DFP 
(diisopropylfluorophosphate) which inactivates all active senne 
proteinases, substrate-derived chloromethyl ketones are capable of 
more selective inhibition depending upon the substrate peptide 
attached to the chloromethyl ketone group [Shaw 1975]. GGA-CMK 
is a relatively selective inhibitor of uPA [Kettner and Shaw, 1979]. 
This study (Figure 3.4) shows that GGA-CMK inhibits both soluble 
purified uP A (open circles) and receptor-bound endogenous uP A 
activity expressed on the surface of 2xl 05 HCT 116 cells (filled 
circles) m a dosage-dependent fashion. For receptor-bound uP A 
the 150% = l.OJ.1M was lower than that for 100 miU soluble purified 
uPA 050% = 2.9J.1M) suggesting that the binding of uPA to uPAR 
increases its sensitivity to inhibition by GGA-CMK. 
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Figure 3.4: Inhibition of receptor-bound uPA activity 
by GGA-CMK 
Confluent HCT116 cells (filed circles) (2x105 /well) or purified uP A 
(open circles) (100 miU/well) were incubated at 370c for 2h with 100 11M 
VLL-AMC, 2 jlg/ml purified human plasminogen, and increasing 
concentrations of GGA-CMK in 50 mM Tris-HCl pH 8.0, containing 0.1 M NaCl 
(200 Ill). Fluorescence was measured and calculated as uPA activity according 
to the internal uPA standard curve. The data represent the mean of triplicate 
samples. The experiment was repeated at least 3 times. 
1 
0 
3.3. d n 1 
end 
I-2 and ylo [Baker et 
by 
cancer 
1990]. 
~bou 
ons 
aving y 
the a number of uPA inhibitors on 
u activity (Sections 3.3.1.1 to 3.3.1.3), it was 
to determine whether simi effects were 
examining ECM degradation "driven" cell 
3.3.2.1 en dent d a n 
s on ]-ser ne 
s a 
u on 
3 e counts 
umn 1) were 3 ]-ser·ne 
m s 15.8 
to 688 ± 
g respectively). This res t i cates that l-depe ant 
ECM degradation was minimal in cell cultures 
plasminogen. 
the absence of 
98 
gq 
Figure 3.5: Plasminogen-dependent extracellular 
matrix degradation by HCT116 cells 
HCT116 cells (0.5x106/well) were seeded onto [3H]serine labelled ECM in 
RPMI/2% FCS. During 24h culture, HCT116 cells formed a monolayer on the 
ECM. The culture medium was then replaced with fresh RPMI (column 1) or 
fresh RPMI containing purified human plasminogen (20 f.,lg/ml) (columns 2-
5) and the culture was continued for another 6h. [3 H]serine released during 
the 6h was measured and expressed as the percentage of total labelling. 
Minus cells (column 2), addition of tranexamic acid (0.1 mM) (column 4) and 
TrasylolR (O.l!J.M) (column 5) were used as controls. The data represent the 
mean of duplicate samples. The experiment was repeated 3 times. 
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Figure 3.6: ECM degradation by colon cancer cells with 
different receptor-bound uPA activity 
HCT116 cells (open circles) or KM12SM cells (open squares) were 
seeded onto [3H]serine labelled ECM (0.5x106 cells I well for HCT116; 0.75x106 
cells I well for KM12SM). After 24h the culture medium was replaced with 
fresh RPMI containing purified human plasminogen (20 jlglml) and the 
culture was continued for 2 to 8h (HCT116), or 2 to 6h (KM12SM). [3H]serine 
release in the presence of plasminogen was measured and expressed as the 
percentage of total labelling. The data represent the mean of duplicate 
samples. The experiment was repeated 3 times for KM12SM and more than 3 
times for HCT116. 
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Figure 
ECM 
3. 7: Effect 
degradation 
of PAI-2 on HCT116 cell-mediated 
HCT116 cells were seeded onto [3H]serine labelled ECM (0.5x106 
cells/well). After 24h the culture medium was replaced with fresh RPMI 
containing purified human plasminogen (20 ll g/ml) and increasing 
concentrations of PAI-2. The culture was continued for 6h. [3H]serine release 
during the 6h was measured and expressed as the percentage of total 
labelling. The data represents the mean of triplicate samples. The experiment 
was repeated 2 times. 
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HCT116 cells were seeded onto [3H]serine labelled ECM .5x106 
cells/well) in medium. After 24h the culture medium was 
aced with fresh RPMI containing human plasminogen 
Jlg/ml) and increasing concentrations Joride. The culture was 
continued 6h. [3 H]serine release during the 6h was measured and 
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The was 3 

Figure 
ECM 
3.9: Effect of GGA-CMK on HCT116 cell-mediated 
degradation 
HCT116 cells were seeded onto [3 H]serine labelled ECM (0.5x 106 
cells/well) in serum-containing medium. After 24h the culture medium was 
replaced with fresh RPMI containing purified human plasminogen (20 
f..lg/ml) and increasing concentrations of GGA-CMK. The culture was 
continued for 6h. [3 H]serine release during the 6h was measured and 
expressed as the percentage of total labelling. The data represents the mean 
of triplicate samples. The experiment was repeated 3 times. 
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weight uncharged chemical inhibitors (amiloride 
GGA-CMK), were found to inhibit cell surface uPA as efficiently as 
they inhibited soluble purified uPA preparations. 
It has been suggested that receptor-bound uPA, not soluble 
uP A is the main initiator of plasminogen-dependent pericellular 
proteolysis during cancer cell mediated degradation of ECMs. Hollas 
et al. ( 1991) reported that the ability of colon cancer cell lines to 
invade Matrigel R correlated with the concentration of receptor-
bound uPA found on their surfaces. The ability of cells to invade 
MatrigeiR was not augmented even when cells were induced to 
secrete up to 8 times as much uPA (without alteration of 
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bound uPAR) and conversely increased invasion was attained after 
preincubation of cells with exogenous uPA to fully occupy any 
unoccupied uPARs [Hollas et al., 1991]. When HCT116 and PC3 
(human prostate carcinoma) cells were genetically engineered to 
express a completely inactive mutant of uP A in which the active 
site serine residue (ser3 56) was changed to alanine, the level of 
cell-bound active uPA decreased by 95% via a mechanism that 
involved competition for receptors; and decreased cell surface uPA 
activity was associated with decreases in cell surface plasminogen 
activation and in ECM degradation or MatrigeiR invasion by these 
cells [Cohen et al., 1991; Crowley et al., 1993]. 
The plasminogen-dependent ECM degradation by colon cancer 
cells observed in this study is initiated primarily by endogenous 
receptor-bound uPA since: 
• any soluble uPA which had accumulated in the culture medium 
was removed prior to the addition of plasminogen 
• plasminogen-dependant ECM degradation was abolished by 
addition of T A which blocks plasminogen binding to cell 
surfaces 
• plasminogen-dependant ECM degradation was inhibited in the 
presence of the physiological inhibitor uP A inhibitor P AI -2 
• plasminogen-dependant ECM degradation was inhibited in the 
presence of the chemical inhibitors of uPA (amiloride and GGA-
CMK) 
• the potential of HCT 116 and KM 12SM cells to degrade intact 
ECMs correlated closely with the receptor-bound uPA activity 
found on their cell surfaces. 
These results reaffirm the view that uPA inhibitors may have 
therapeutic potential for the prevention and treatment of cancer 
1 1 0 
invasion and metastasis. Among the inhibitors tested in this study 
PAI-2 was the most effective inhibitor (150 % = 66T]M), with GGA-
CMK being a far less effective inhibitor Oso% = 12~-tM) and 
amiloride being a relatively weak inhibitor Oso% = 230~-tM) of ECM 
degradation by HCT 116 cells. In addition to its effectiveness at low 
concentration, one additional potential therapeutic advantage of 
recombinant human PAI-2 (in contrast to other proposed anti-
metastatic strategies like the use of chemical uP A inhibitors or 
uPA-inhibitory MAbs) is that human PAI-2 is well tolerated (eg: 
during pregnancy) and hence is less likely to be immunologically 
reactive than a foreign chemical or antibody r \<ruitth()f tA. (!({.) r<f5$J 
Recently, a new class of selective uP A inhibitors has been 
developed by Towle et al. ( 1993) based on modifications of 
amiloride. These new competitive inhibitors are more efficient (20-
100 fold) than amiloride in inhibiting both free and cell surface 
uP A as well as cell surface uP A-mediated cellular degradati ve 
functions [Towle et al., 1993]. These new synthetic uP A inhibitors 
promise new horizons in the development of therapies directed at 
preventing the invasive phenotype of malignant cancer cells. 
Cajot et al., (1990) reported that P AI -1 may be a natural 
inhibitor of extracellular matrix degradation by tumour cells such 
as fibrosarcoma and colon carcinoma cells. In an ECM degradation 
assay, PAI-l regulated ECM breakdown. PAI-l inhibited matrix 
solubilisation by tumour cells, whereas monoclonal antibodies to 
PAI-l increased it [Cajot et al., 1990]. But used as an anti-invasion 
reagent, exogenous PAI-l may have senous potential for 
interfering with the fibrinolysis system because of its stronger 
inhibitory effect on tP A. 
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CHAPTER 4 
EFFECTS of ANTISENSE SUPPRESSION OF uPAR GENE 
EXPRESSION IN HCT116 CELLS 
4.1 Introduction 
Use of antisense RNA has proven to be a powerful tool for 
manipulation of specific gene , expression. This technology has the 
potential to impede information flow from DNA to protein via RNA 
by introducing a sequence complementary to a mRN A molecule 
coding for a specific target protein. An RNA duplex is formed that 
is either rapidly degraded, inaccessible to normal nuclear 
processmg, or untranslatable into the target protein [Izant and 
Weintraub, 1985; Inouye 1988; Helene and Toulme, 1990]. 
Antisense transcripts may be generated by transfecting cells with 
antisense genes that will be subsequently transcribed or by 
introducing 'ready-to-use' RNAs synthesised in vitro using 
microinjections [Inouye 1988; Helene and Toulme, 1990]. Use of 
the former strategy requires the production of an antisense 
plasmid that can be constructed by inserting the sequence of 
interest into a vector in the inverted (or antisense) orientation 
relative to the promoter [Izant and Weintraub, 1985; Khokha et al., 
1989; Sasaki et al., 1993]. The use of antisense technology was 
employed as an additional means of interfering with uP AR 
expression that many published reports and results reported in 
this thesis have suggested, ts so important for cell surface 
plasminogen activation. 
Purified uP AR has an apparent molecular weight of 55 to 60 
kDa and is a single-chain glycoprotein [Nielsen et al., 1988; 
Estreicher et al., 1989; Behrendt et al., 1990]. NH2- term in a 1 
1 I 3 
sequence data [Behrendt et al., 1990] have allowed the 
construction of an oligonucleotide probe and the isolation of a full-
length eDNA (1.4 kb) coding for uPAR [Rolden et al., 1990]. It has 
been shown in the previous chapters that in colon cancer cell lines 
endogenous receptor-bound uPA activity correlated well with the 
binding capacity of uPAR on the cell surface and that receptor-
bound uPA may be the main initiator of ECM degradation by colon 
cancer cells. In this chapter, the role of uPAR in determining colon 
cancer cell-mediated ECM degradation is examined directly by 
genetic manipulation of uPAR expression. 
HCT 116 cells were transfected with a plasmid encoding a 
fragment of the uPAR eDNA in the antisense orientation and 
endogenous uP AR binding capacity; endogenous receptor- bound 
uP A activity and plasminogen-dependent ECM degradation were 
compared. 
4. 2 Materials & Methods 
4.2.1 Materials 
The 1.144kb human uP AR cDN A and the human 18 S 
ribosomal DNA (18S rDNA) were kind gifts from Dr. E. K. 0. 
Kruithof, Lausanne, Switzerland and Dr. B. E. H. Maden, University 
of Liverpool, UK respectively. Plasmid pXT I and the mammalian 
transfection kits were obtained from Stratagene, La Jolla, USA. 
Restriction endonucleases, T7 QuickPrime T M Kit and dNTP were 
purchased from Pharmacia, Australia Pty. Ltd. Moloney murine 
leukemia virus reverse transcriptase, RN ase inhibitor (RNasin) and 
RNA molecular markers were obtained from Promega Corporation, 
Madison, USA. (a-32P)-dCTP was purchased from Amersham Ltd., 
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Purified Bam HI fragment of uPAR eDNA (498-1083) was ligated into 
the Bgl II site of the retroviral vector pXTl (Fig. 1, A) to generate plasmid 
pXT/uPAR (Fig. 1, B) in which the inserted uPAR eDNA was under 
the control of the thymidine kinase (TK) promoter. 
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Purified asmid pXT1, pXT/uPAR15 and pXT/uPARll were digested 
with Nco I (lane 2, 4, and 6) and then electrophoresed on a 1% agarose gel. 
The smaller fourth so produced (lane 668 ) indicates that the 
uPAR insert is in the sense orientation, and the larger fourth fragment (lane 
6, 813 indicates the antisense orientation. Lane 1, 3, and 5 are 
samples of pXTl, pXT/uPAR15 and pXT/uPAR11. 
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RPMI supplemented 1 0% FCS and 1 mg/ml 18. G418-
resistant clones were subcultured and passaged m G418-containing 
medium. A range of clones of different passage number was stored 
at -7o0c in RPMI containing 20% FCS and 10% DMSO. 
4.2.4 eDNA probes 
32P-labelled eDNA probes were prepared as outlined by the 
random priming method of Ausubel et al., ( 1987). 
4. 2. 5 Genomic DNA preparation and Southern blot 
analysis 
1 1 8 
Genomic DNA was prepared by the method of Blin and 
Stafford (1976). Transfected or untransfected cells were harvested 
with trypsin and cell pellets were digested at soOc overnight with 
O.lmglml of proteinase K in a buffer containing 0.5% SDS, 25mM 
EDTA, lOmM NaCI and lOmM Tris-HCI (pH 8.0). Genomic DNA was 
purified by multiple extractions with equal parts of buffer 
equilibrated with a mixture of phenol and chloroform:isoamyl 
alcohol (24: 1). Residual RNA was removed by treatment of the 
DNA at 370c for lh with lglml DNase-free RNase in the presence 
of 0.1% SDS. This was followed by organic extraction as described 
above. The purified DNA (15~g) was digested at 370e overnight 
using 20U of various restriction endonucleases (eg: Eco Rl, Hind 
HI, or Xba I). The digested DNA was electrophoresed in a 0.8% 
agarose gel and denatured in 0.5 M NaOH, 1.5 M Nael at room 
temperature for 1 h. After neutralisation, the DNA in the gel was 
transferred to a nitrocellulose membrane. Prehybridization was 
carried out at 420c for 16h in 50% (vollvol) formamide I 6x sse I 
5x Denhardt's solution I 2% Sarcosyl I 200~glml salmon sperm 
DNA. Hybridization with 32P-labelled uPAR eDNA (at I - 3xi06 
cpmlml) was carried out in the same buffer for 48h at 420 C . 
Membranes were washed in 2x SSC I 0.1% SDS once for 15min at 
420c and then in O.lx sse I 0.1% SDS twice for 15min at ssOc. 
The membranes were exposed to Kodak XAR film at -700c using 
intensifying screens and multiple film exposure times were used 
to ensure linearity of band intensities. 
4. 2. 6 RNA preparation and Northern blot analysis 
Total cellular RNA was purified from transfected or 
untransfected cells using the guanidinium isothiocyanate method. 
RNA samples were electrophoresed on 0.8% formaldehyde-
containing agarose gels, transferred to a nitrocellulose membrane 
and further processed according to the method of Ausubel et al. 
( 1987). Prehybridization was carried out at 420e for 16h in 50% 
(vollvol) formamide I 6x sse I 5x Denhardt's solution I 2% 
Sarcosyl I 200~-Lglml salmon sperm DNA. Hybridization with 32p_ 
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labelled eDNA (at 1 - 3x I 06 cpm/ml) was carried out in the same 
buffer for 48h at 420e. Membranes were washed in 2x SSe I 0.1% 
SDS once for 15min at 420e and then in O.lx SSe I 0.1% SDS twice 
for 15min at 550c. The membranes were exposed with multiple 
film exposure times to Kodak XAR as above. The intensities of 
mRN A bands m the autoradiographs were scanned and 
quantitated by a video densitometer (Model 620, BioRad) and 
mRNA intensities were calculated relative to the intensity of the 
ISS rRNA internal control. 
4. 2. 7 Polymerase chain reaction 
A pair of oligodeoxynucleotide primers was chemically 
synthesised according to the published uPAR cDN A sequence 
[Rolden et al., 1990]. They were uPARex5s, 5' GeG Tee AAA GGA 
TGA eeG eeA (520~540) and uPARex7a, 5' eAe AGT eTG GeA GTe 
ATT AGe (1029~1009). 
DNA PeR was performed in a volume of 1 001!1, containing SOng 
of genomic DNA, 2 units of Taq DNA Polymerase, IOpmol of each 
primer, 20nmol of each dNTP in 50mM Kel, IOmM Tris-HCI (pH 
8.3), 1.5mM Mgel and 0.001% (wlv) gelatin and the mixture was 
overlaid with 60!!1 of mineral oil. After the mixture was denatured 
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by heating at 960 C for 5min, the reaction was processed by a 
Perkin-Elmer DNA thermal cycler for 25 cycles, with a 
denaturation step at 960c for lmin, an annealing step at 550c for 
lmin and an extension step at 720c for 2min. 15!-ll of PCR product 
was electrophoresed on a 1 % agarose gel and stained with 
ethidium bromide. 
RT(reverse transcription)-PCR was performed according to the 
method of Mason et al., (1993). In detail, 501lg of total cellular RNA 
was mixed with 20 units of RNasin and incubated at 650c for 5min 
and then incubated at 420 C for 1 h with one of the primers (1 0 
pmol), Moloney murine leukemia virus reverse transcriptase (200 
units) and 1 mM of each dNTP in 20!-ll of reaction solution 
containing 75mM KCl, 50mM Tris-HCI (pH 8.3) and 3mM MgCl. The 
reverse transcription was stopped by heating at 960c for 5min. To 
2 01-11 of single-stranded cDN A, 80!-ll of PCR reaction solution 
containing 10 p mol of the other primer, 2 units of Taq DNA 
Polymerase and 2011mol of each dNTP were added and the mixture 
overlaid with 60!-ll of mineral oil. After the mixture was denatured 
by heating at 960 C for 5min, the reaction was processed in a 
Perkin-Elmer DNA thermal cycler for 25 cycles, with a 
denaturation step at 960c for lmin, an annealing step at 550c for 
lmin and an extension step at 720c for 2min. A direct PCR using 
both the primers and total cellular RNA as the template (i.e. the 
reverse transcription step was omitted) was performed as a 
control. 15!-ll of PCR products were electrophoresed on a I% agarose 
gel and stained with ethidium bromide. 
4.2.8 12 SJ.uPA binding assay 
The total uPAR content and its dissociation constant in the 
subclones of transfected HCT 116 cells were determined and 
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Fluorescence intensity, calibrated to uP A standards, was 
measured as described in Section 2.2.6. Soluble uPA activity which 
had accumulated in the culture medium of the transfected, sham-
transfected and untransfected sublines were also measured usmg 
the method described in Section 2.2.6. 
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transfected an antisense plasmid (pXT /uP ARa) constructed by 
serting the Bam HI/Bam HI fragment of uP AR cDN A into a 
retroviral vector pXT 1 in an antisense orientation relative to the 
TK promoter. To control for any effects which were due to the 
transfection procedure itself, HCT 116 cells were transfected with 
the empty vector, pXT 1 (ie: sham-transfected). After selection in 
G418-containing medium, more than 300 neomycin-resistant 
clones were obtained and a selected number of these clones were 
characterised in terms of: 
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• the integration of exogenous uPAR eDNA into the genome of the 
cell 
• antisense RNA expression within the cell 
• uP AR binding capacity of the cells 
• endogenous receptor-bound uPA activity of the cells 
• ability of transfected cells to degrade ECM in the presence of 
plasminogen. 
4.3.1 Integration of exogenous uPAR eDNA into the 
genome of HCT116 cells 
Genomic DNA isolated from transfected and untransfected 
HCT116 cells was digested with Eco RI and separated by 0.8% 
agarose gel electrophoresis. The DNA in the gel was transferred 
onto a nitrocellulose membrane and hybridised with 32P-labelled 
uPAR eDNA. Southern blotting showed that untransfected HCT116 
cells (Figure 4.3, lane 3) revealed three bands (1 0.1, 4.5 and 2.7kb) 
with clone XTO (sham-transfected with empty vector pXT 1, Figure 
4.3, lane 6) having the same restriction pattern. In contrast, 3 out 
of 4 antisense-transfected clones revealed additional bands of 
0.9kb in XTIIB (Figure 4.3, lane 1), 2.6 and 6.0kb in XT114 (Figure 
4.3, lane 2) and more than 12kb in XT112 (Figure 4.3, lane 4). No 
extra band was found in the XT13D clone (Figure 4.3, lane 5). The 
extra bands provide evidence of integration of one or more copies 
exogenous uP AR cDN A into the genome of transfected cells m the 
clones XT 11 B, XT 112 and XT 114. The different sizes of the 
additional bands indicate that the exogenous uPAR eDNA has 
integrated at different sites and multiple sites in the genome of 
these transfected clones. As described by Shoemaker et al. (1980), 
in the integration reaction, the target sites on the host DNA are 
selected with at most a low specificity at the sequence level, and 
there is no obvious pattern common to the incorporation target 
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Figure 4.3. Southern blotting analysis of Genomic DNA 
isolated from transfected HCT116 cells 
Genomic DNA isolated from transfected and untransfected HCT116 cells 
was digested with Eco RI, and then separated on a 0.8% agarose gel. DNA in 
the gel was transferred onto a nitrocellulose membrane and hybridised with 
3 2p_Jabelled uPAR eDNA. The arrangement of samples on the filter: XTllB 
(lane 1, transfected with antisense plasmid), XT114 (lane 2, transfected with 
antisense plasmid), untransfected HCT116 (lane 3), XT112 (lane 4, transfected 
with antisense plasmid), XT13D (lane 5, transfected with antisense plasmid), 
and XTO (lane 6, transfected with empty vector). Exposure time was 7 days. 
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synthesi NA of HCT116 
50 ng of DNA isolated from XTO (column 2), XT11 (column 3), 
XT11'17 (column (column 5), XT114 (passage 10) (column XT114 
(passage 25) (column and uPAR eDNA (column 1) were as the 
templates. The oligodeoxynucleotide primers used here were uPARex5s 
uPARex7a (specific for the Bam HI fragment of uPAR eDNA). 15 
were electrophoresed on a 1% agarose gel and stained with 
bromide. Arrow indicates the size of the between 
uPARex5s and uPARex7a (509bp). 
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Because sense insert in plasmid pXT /uP ARa only a 
coding fragment of the cDN A of uP AR and lacks both the 5' and 3' 
regions of full length cDN A, the size of the antisense RNA 
transcribed from the plasmid after integration into the genome of 
the cells cannot be predicted. If transcription started from the TK 
promoter (refer to Figure 4.1) and was terminated by the LTR, the 
size of the sequence containing uPAR antisense RNA would be 
-1.4kb, thus the l.4kb band may represent both native uP AR 
mRNA and the antisense transcript. The Northern blot results 
therefore do not provide clear evidence of expression of uP AR 
antisense RNA. 
Figure 4.5. Northern blotting analysis of mRNA isolated 
from transfected and untransfected HCT116 cells 
Total cellular RNA was purified from transfected or untransfected cells 
using the guanidinium isothiocyanate method. RNA samples were 
electrophoresed on a 0.8% formaldehyde-containing agarose gels, 
transferred to a nitrocellulose membrane and hybridised with 32P-labelled 
uPAR eDNA and then with 18S eDNA. The membranes were exposed to Kodak 
XAR film 9 days for uPAR (track A) and lh for 18S rRNA (track B). Samples on 
the filter were XT13D (lane 1), HCT116 (lane 2), XTO (lane 3), XT112 (lane 4), 
XT119 (lane 5), XT11'17 (lane 6), and XT114 (lane 7 and lane 8). 
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RT-PCR provides an alternative approach to examme an RNA 
molecule with known sequence [Mason et al., 1992]. In this study, 
reverse transcription was performed, usmg total cellular RNA 
isolated from untransfected HCT 116 as the template and one of the 
two oligodeoxynucleotides (uPARex5s, 520~ 540; uPARex7a, 
1 029~ 1009) as the primer. The resulting single strand eDNA was 
amplified by PCR and analysed by electrophoresis on 1% agarose 
gel. As shown in Figure 4.6, a clear band with expected size (509 
bp) was obtained when the antisense primer (uPARex7a) was used 
in the reverse transcriptase reaction (Figure 4.6, lane 2) indicating 
that a single strand DNA with complementary sequence to uPAR 
mRNA had been transcribed in the reverse transcription step and 
this band was absent when the sense primer (uPARex5s) was used 
in the reaction (Figure 4.6, lane 1 ), because the sense pnmer 
cannot hybridize to uP AR mRN A to initiate the reverse 
transcriptase reaction. 
Direct PCR (Figure 4.6, lane 3) usmg total cellular RNA as the 
template was performed to control for direct amplification due to 
the PCR reaction itself. Only a very faint band was seen at 509 bp 
indicating that the mRNA was not a good template for Taq DNA 
Polymerase. 
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Lane 1 and 2 show RT -PCR products, lane 3 shows direct PCR product, 
and lane 4 shows the molecular weight standard, 1-kh DNA ladder. At the 
reverse transcriptase reaction step, a single primer, uPARex5s (lane 1) or 
uPARex7a (lane 2) was used. Arrow indicates the expected size of the 
between uPARex5s and uPARex7a. 
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Figure 4. 7. Agarose gel electrophoresis of RT -PCR products 
synthesised from total cellular RNA isolated from 
antisense-transfected clone and control cells 
Lanes 2, 3, 5 and 6 show RT -PCR products, lanes 4 and 7 show direct PCR 
products, and lane 1 and 8 shows the molecular weight standard, 1-kh DNA 
ladder. The total cellular RNA was isolated from antisense-transfected clone 
XT112 (lanes 5, 6 and 7) and the control cells (XTO) (lanes 2, 3 and 4 ). Single 
primer, uPARex5s (lanes 2 and 5) or uPARex7a (lanes 3 and 6) was used in the 
reverse transcriptase reaction. Arrow indicates the expected size of the 
fragment between uPARex5s and uPARex7a. 
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uPAR binding capacity of antisense-transfected clones was measured using 
a radioactive uPA binding assay (Refer to method section of Chapter 2). The 
data represent the mean and SE of three experiments. P > 0.05 when b vs a; P 
< 0.05 when c, d, and e vs a orb; P > 0.05 when f vs a or b. P > 0.05 when a' vs 
b',c',d', and e'. P < 0.05 when a' vsf'. 
4.3.4 Changes of endogenous receptor-bound uPA 
activity in antisense transfectants 
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As discussed previously, expression of uPAR is one of the main 
parameters which determines the level of endogenous receptor-
bound uP A activity in cell lines expressmg both uP A and uP AR. 
Therefore, one would expect that changes of endogenous receptor-
bound uPA activity should be expected In the antisense 
transfectants. This study was conducted using the indirect 
receptor-bound uPA activity assay and the results are shown m 
Table 4.2. Compared to untransfected HCT 116 cells (354 ± 35 
miU/106 cells), endogenous receptor-bound uPA activity was not 
altered m clone XTO (372 ± 46 miU/1 o6 cells), but was decreased 
in the all antisense-transfected clones XT112 by 32% (240 ± 17 
miU/106 cells), XT119 (by 55% 159 ± 21 miU/106 cells), XT114 
(by 58% 148 ± 19 miU/106 cells) and XT11'17 by 78% ( 79 ± 11 
miU/1 o6 cells). 
Table 4.2 Receptor-bound uPA activity of antisense-
transfected clones 
miU/106 cells % of control 
HCT116 354 ± 3sa 100 
XTO 372 ± 46b 105 
XT112 240 ± 17C 68 
XT11'17 79 ± 11d 22 
XT119 159 ± 21e 45 
XT114 148 ± 19f 58 
Receptor-bound uP A activity of antisense-transfected clones was measured 
using the indirect fluorescence assay (Refer to method section of Chaptor 2). 
The data represent the mean and SE of four experiments. P > 0.05 when b vs 
a; P < 0.05 when c, d, e, and f vs a or b. 
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uPA activity accumulated in the culture medium of antisense-transfected 
clones was measured using the indirect fluorescence assay (Refer to method 
section of Chapter 2). The data represent the mean and SE of four 
experiments. P > 0.05 when b vs a; P < 0.05 when c, d, e, and f vs a or b. 
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4. 3. 5 ECM degradation by antisense transfectants 
Both untransfected HCT116 cells and the antisense-transfected 
cells formed near-confluent monolayers on the [3 H]-serine labell~d 
ECM after 24h culture in RPMI containing 2% FCS. After the 
addition of a range of purified plasminogen concentrations (0 -
24~g/ml) ECM degradation by control untransfected cells and the 
XT 114 and XT 11' 17 antisense-transfected clones was measured. 
Significant plasminogen-dependant ECM degradation was mediated 
by untransfected cells (Figure 4.8, open circles) but ECM 
degradation by clones XT114 (open triangles) and XT11'17 (open 
squares) did not occur at the lower concentrations of plasminogen 
and ECM degradation remained lower even at high concentrations 
of plasminogen (24 ~g/ml). At 24 ~g/ml plasminogen, ECM 
degradation decreased significantly for both XT 114 and XT 11' 17 
antisense-transfected clones ( 42% decrease for XT 114 and 60% 
decrease for XT 11' 17) when compared to that of untransfected 
cells . 
Similar results were obtained when these cells grown on the 
ECM labelled with a mixture of [3 H]leucine, [3 H] 1 y sine, 
[3 H]phenylalanine, [3 H]proline and [3 H]tyrosine rather than [3 H]-
serine. As shown in Figure 4.9, the amount of [3H]-labelled ammo 
acids released from the ECM by clone XTO (HCT 116 transfected 
with empty plasmid) (3450 ± 389 cprn!well, column 2) was similar 
to that released by untransfected HCT 116 cells (3372 ± 163 
cpm/well, column 1) (P>0.05). In contrast, the [3 H)-labelled amino 
acids released by clone XT112 (2678 ± 215 cprn!well, column 5), 
clone XT 119 (2500 ± 100 cpm/well, column 4) and clone XT 11' 17 
(1377 ± 164 cpm/well, column 3) represented a significant 
reduction in ECM degradation of 21%, 26% and 61% respectively 
when compared to untransfected HCT 116 cells. 
Figure 4.8. 
transfected 
Plasminogen-dependent ECM degradation 
and untransfected HCT116 cells 
by 
Untransfected HCT 116 cells (open circles) and antisense-transfected 
clones, XT114 (open triangles) and XT11'17 (open squares) were cultured on 
[3H]-serine labelled ECM in culture medium (RPMI/2% FCS) for 24h to form a 
near-confluent monolayer, and then the culture medium was replaced with 
fresh medium containing increasing concentrations of plasminogen (0-24 
J..l g/ml). The cultures were continued for another 24h and [3 H]- serine 
released into the medium was measured. The data represent mean and SD of 
triplicate samples. The experiment was repeated 3 times. 
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Figure 4.9. ECM degradation 
untransfected HCT116 cells 
by transfected and 
HCT116 (column 1) and transfected subclones, XTO (column 2), XT11'17 
(column 3), XT119 (column 4) and XT112 (column 5) were cultured on ECM 
labelled with [3H]-amino acids in the culture medium (RPMl/2% FCS) for 24h 
to form a near-confluent monolayer, and then the culture medium was 
replaced with fresh medium containing 20 ~g/ml plasminogen. The cultures 
were continued for another 24 h and [3 H]-amino acids released into the 
medium were measured. The data represent the mean and the SD of triplicate 
samples. The experiment was repeated at least 3 times. 
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4. 4 Discussion 
The expression of uPAR in HCT 116 cells was selectively 
blocked by stably transfecting an antisense eDNA fragment into the 
cells. The stable transcription of the antisense construct in the 
antisense transfectants was confirmed by RT -PCR technique 
(Figure 4.7). According to the Northern Blot analysis (Figure 4.5), 
the hybridization of the antisense transcripts (antisense uPAR 
RNA) with the sense RNA (uPAR mRNA, transcribed from the uPAR 
gene) may occur in the nucleus resulting in inhibition of RNA 
processing and transport. The result of antisense transfection was a 
reduction in the levels of mature mRNA available in the cytoplasm 
for translation and cell surface attachment of uPAR protein [Kim 
and Wold, 1985]. Inhibition of uP AR protein expression was found 
in three out of four antisense-transfected clones, but r~.Ilted in 
only a moderate (30 - 40%) decrease in uPAR binding capacity 
(Table 4.1 ). To obtain stronger inhibition of uPAR expression, uPAR 
antisense plasmids using the AUG initiation codon or the full-
length mRNA as the target may be more successful [Helene and 
Toulme, 1990]. In one antisense-transfected clone, the uP A binding 
capacity was slightly increased (18% up) with a significant decreas 
in affinity but the mechanisms involved in this outcome are not 
known. 
As expected, the decrease in uPA binding capacity was 
associated with decreased receptor-bound endogenous uPA 
activity (Table 4.2) and the excess uPA produced by the cells 
accumulated in the culture medium (Table 4.3). But the changes m 
receptor-bound endogenous uPA activity (32-78% decrease m 
XT112, XT119, XT114 and XT11'17) did not closely correspond to 
the changes in uP AR binding capacity (32-34% decrease m 
XT11 I 17' XT112 and XT119; but 18% increase in XT114) 
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indicating that factors other than uPAR and uPA (eg: PAis) may be 
involved. As discussed earlier, receptor-bound endogenous uPA 
activity on the colon cancer cell surface is determined by uPAR 
binding capacity, the amount of uP A available for binding, 
endogenous PAis as well as the ratio of potent active uPA and 
inactive ligands occupied on uPAR. Therefore, in addition to 
changes in uPAR expression, other factors may also alter receptor-
bound endogenous uPA activity including changes in the relative 
expression of uPA and PAI-l in different subclones of transfected 
HCT 116 cells. Because an established tumour cell line such as 
HCT 116 may consist of some subpopulations that may differ m 
biological properties [Fidler, 1990]. 
Selective inhibition of uPAR expression provided an approach 
to examine the involvment of receptor-bound uPA or soluble uPA 
as a main initiator of the pericellular proteolysis involved m 
tumour cell . . mvaswn. Compared to controls, the ability of 
antisense-transfected clones to initiate plasminogen-dependant 
ECM degradation was markedly reduced and this was correlated 
with changes m receptor-bound endogenous uP A activity. 
Furthermore, soluble uPA accumulated in the culture supernatant 
wh,'d, ~We. 
medium of antisense-transfected cells to level~much higher than 
those of normal controls. 
In total, these results demonstrate that receptor-bound uPA, 
and not soluble uPA, is most likely the main initiator of pericellular 
plasminogen activation and subsequent proteolysis. 
4.5 Summary 
In summary, expression uPAR m the colon cancer cell line 
HCT116 was selectively reduced by transfection using uPAR-
antisense-containing plasmid resulting m reduction m the 
1 4 1 
receptor-bound uPA activity and in plasminogen-dependent ECM 
degradation. These results provide direct evidence that expression 
of uPAR is central to the process of malignant cancer cell 
pericellular proteolysis. 
CHAPTER 5 
THE ROLE OF RECEPTOR-BOUND uPA IN COLON 
CANCER METASTASIS 
5.1 Introduction 
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The in vitro studies presented here and elsewhere [Hollas e t 
al., 1991; Cohen et al., 1991; Crowley et al., 1993] suggest that 
receptor-bound uPA is central to the initiation of degradation the 
extracellular matrix (ECM) by colon cancer cells and that this 
process can be inhibited by blocking uPAR expression or by 
inhibiting receptor-bound uP A activity directly. As discussed in 
Chapter 1, tumour metastasis 1s a multi-step process in which 
vanous tumour and host factors are involved. But whether 
receptor-bound uPA is an essential step in colon cancer metastasis 
or whether it merely "enhances" this process is not clear. Moreover 
little is known about which step(s) in the metastatic process 
require receptor-bound uPA-initiated proteolysis from in vivo 
studies. The purpose of the studies outlined in this Chapter was to 
investigate the role of receptor-bound uP A in the process of 
experimental colon cancer metastasis in vivo . The experimental 
approach employed here involved: 
• (a) establishment of various nude (Nu/Nu) mouse models of 
human colon cancer metastasis; 
• (b) examination and comparison of the metastatic potential of 
two colon cancer cell lines (ie: HCT116 & KM12SM cells) usmg 
different models; 
• (c) comparison of the metastatic potential of uPAR antisense-
transfected HCT 116 cells compared to control untransfected 
cells; and 
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• (d) evaluation of the effects of the uPA and plasmin inhibitors 
(eg: GGA-CMK, amiloride and TrasylolR) on the formation of 
experimental colon cancer metastases. 
Human colon cancer cells grow and spread in athymic (nude) 
mice after intracaecal, intrasplenic or intravenous injection but not 
after subcutaneous inoculation. After intracaecal injection (now 
termed the "intracaecal" model), human colon cancer cells grow at 
the injection site and spread to the mesenteric lymph nodes and 
the liver. When colon cancer cells are injected directly into the 
spleen (now termed the "intrasplenic" model), the liver is the 
preferred target organ for the formation of metastases. In contrast, 
the lungs are main site for "metastases" formation when human 
colon cancer cells are injected directly into the tail vein of nude 
mouse (now termed the "intravenous" model) [Kozlowski et al., 
1984; Giavazzi et al., 1986a,b; Morikawa et al., 1988]. In this study, 
the nude mouse was chosen as the recipient and all of the methods 
described above for introducing colon cancer cells into nude mouse 
(except subcutaneous inoculation) were employed. 
5. 2 Materials and Methods 
5.2.1 Materials 
Methoxyflurane was obtained from Abbot Laboratories, North 
Chicago, USA. AlzetR mini-osmotic pumps were from A I z a 
Corporation, Palo Alto, California, USA. The source of other reagents 
and drugs such as amiloride, Glu-Gly-Arg chloromethyl ketone 
(GGA-CMK) and TrasylolR used in these experiments was as 
described in Chapter 3. 
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5.2.2 Animals 
Three to four-week-old athymic mice (Swiss outbred nude 
Nu/Nu mice) were obtained from the Animal Services Division, 
John Curtin School of Medical Research, ANU. Mice were age- and 
sex-matched for each experiment. Throughout all experiments, the 
mice were maintained in a laminar flow cabinet under specific-
pathogen-free (SPF) conditions. 
5.2.3 Cell lines, cell culture and preparation of cancer 
cell suspensions for in vivo injection 
The human colon cancer cell lines HCT 116 and KM 12SM were 
cultured as described in Chapters 2 and 3. Transfected HCT 116 
subclones, XTll' 17 (transfected with uPAR antisense eDNA) and 
XTO (transfected with empty plasmid pXT 1) were generated and 
maintained as described in Chapter 4. To prepare cell suspensions 
for in vivo injection, colon cancer cells were harvested from 
subconfluent cultures by a 2min treatment with 0.25% trypsin and 
0.02% EDT A. The dislodged cells were first washed in serum-
containing medium and then resuspended in HBSS for injection. To 
avoid possible variations in the metastatic potential of cell lines 
from different passage numbers, cells from the same passage 
number were used in all of the in vivo experiments. Transmission 
electron microscopy was performed on samples of each 
preparation of cells before or after the in vtvo injections to test for 
viral contamination. 
5.2.4 Intracaecal and intrasplenic implantation 
Intracaecal and intrasplenic implantation of colon cancer cells 
into nude mouse were performed essentially as described by 
Morikawa et al. ( 1988). Briefly, nude mice were anaesthetised with 
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5.2.6 Statistical Analysis 
The in vivo data were analysed for statistical significance by 
the Chi2 test. 
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(Figure 5.1 histological examination (Figure 5.1 B, c and 
). Eighty mne m1ce were used in these experiments ( 40 mice 
injected with HCT116 cells and 49 mice injected with KM12SM 
cells) and the results are summarised in Table 5.1. 
These experiments indicated that the earliest visible hepatic 
metastases were seen at 21 days post-implantation of cancer cells, 
while visible local tumour growth was seen as early as 12 days 
after implantation. The incidence of local tumour growth at the 
injection site was slightly higher for KM 12SM cells (19 out of 
mice, 38.8%) than for HCT 1 16 cells (1 2 out of 40 mice, 30.0% ). 
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Table 5.2 Formation of hepatic metastases in nude mice 
after intrasplenic injection of human 
cancer cells 
Cell lines Autopsy Splenic Hepatic 
day tumour* metastasis* 
<20 1/3 0/3 
KM12SM >21 19/19 17/1 9 
<20 1/4 0/4 
HCT116 >21 18/18 18/1 9 
* Number of positive mice I number of inoculated mice. 
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Irrespective of route of administration or dose administered, 
neither uPA inhibitors nor plasmin inhibitor had any effect on the 
formation of hepatic metastasis by either HCT116 or KM12SM cells. 
The incidence of hepatic tumour formation was 80% (HCT 116, 
16/20 mice) and 89% (KM12SM, 8/9 mice) in untreated mice. In 
the amiloride-treated groups, hepatic tumour formation was seen 
in all of the mice (12112 mice for HCT116, 14114 mice for 
KM 12SM). In the GGA-CMK-treated group, the incidence of hepatic 
tumour formation was similar to that of untreated group ( 1 11 
1 5 1 
mtce for HCT116, 20/22 mice for KM12SM). TrasyloiR was only 
tested on mice injected with HCT116 cells and all of the mice 
treated with TrasylolR were found to have hepatic tumour foci 
(717 mice). The number and the Size of the hepatic tumour foci 
were similar among the treated and untreated groups (data not 
shown). 
Table 5.3 Effects of 
hepatic 
uP A or plasmin 
metastases by 
inhibitors on the 
inoculating colon experimental 
cancer cells into nude mouse spleen 
Cell Splenic Hepatic 
I in e s Treatment Delivery tumour* metastasis* 
9/9 8/9 K M 12 S M __ _.::;;C..::.o.:.:.nt.:.:.r..::.o.:..l __________ ...;;..:..;;..._ ___ ~..;;._--
HCT116 
Amiloride 
GGA-CMK 
Control 
Amiloride 
GGA-CMK 
TrasyloiR 
Orally 
I-P 
I-V 
S.C pump 
I-P 
I-V 
Orally 
I-P 
S.C pump 
1-P 
I-V 
6/6 6/6 
4/4 4/4 
2/2 2/2 
2/2 2/2 
4/4 3/4 
18/18 17/18 
18/20 16/20 
6/6 6/6 
2/4 4/4 
2/2 2/2 
11/11 10/11 
7/7 717 
*Number of positive mice/number of inoculated mice; all mice were killed 
21 days after intrasplenic injection of human colon cancer cells. I- P: intra-
peritoneal injection; I-V: intravenous injection; S.C pump: delivered by a 
subcutaneous Alzet mini-pump. 
As reported by Kellen et al. ( 1988), the administration of 
amiloride did not visibly affect the well-being of nude mice, their 
intake of water or their body weight even though doses higher 
than those previously reported were used in this study (data not 
shown). 
5.3.3 The inhibitory effect of amiloride on 
pulmonary tumour formation in nude 
after intravenous injection of human 
cancer cells 
mice 
colon 
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To determine the potential of HCT 116 cells to form pulmonary 
metastases after intravenous injection into nude mtce, a 
preliminary experiment was performed. Nine nude mice ( 4 male 
and 5 female) were injected intravenously with HCT 116 cells. No 
visible pulmonary metastases were found m the six mice killed 
less than 29 days after injection, while visible pulmonary 
metastases were obvious in all three mice killed >34 days post-
injection (Figure 5.3A). These results were confirmed by 
histological examination (Figure 5.3B). 
Amiloride has been reported to inhibit experimental 
pulmonary tumour formation in a rat mammary adenocarcinoma 
model possibly through inhibition of cell-surface uPA activity 
[Kellen et al. 1988]. In studies conducted in this thesis, amiloride 
inhibits receptor-bound uPA activity (See 3.3.1.2) and ECM 
degradation by HCT116 cells (See 3.3.3), but had no inhibitory 
effect on experimental hepatic metastasis post intrasplenic 
injection of H CT 116 cells (Table 5.3). 
To test the possibility that receptor-bound uPA activity 1s 
required for colon cancer cells to arrest and grow in the lungs but 
not necessarily in the liver, the effect of amiloride on experimental 
pulmonary metastasis formation using the "intravenous" model 
was investigated. Amiloride was administered either m the 
drinking water (75Jlg/mouse/day) for 6 weeks beginning 24h 
before the i. v. injection of HCT 116 cells, added to the cell 
suspension and injected as a single dose (45.2jlg/mouse) or both 
added to the drinking water and the cell suspension prior to 
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injection. KM 12SM cells were used as a control smce previous 
reports suggest that they rarely form pulmonary metastases after 
1. v. injection [Morikawa et al. 1988]. 
Six weeks after the injection of the colon cancer cells, the mice 
were killed and necropsied and the results are detailed in Table 
5 .4. In mice injected with HCT 116 cells, pulmonary tumour 
formation was found in five out of the six mice. In contrast, only 
116 mice treated with amiloride orally, 116 mice co-injected with 
cells and amiloride and 1/6 mice that were given amiloride both 
orally and intravenously developed pulmonary metastases. Using 
Chi-squared analysis, the incidence of pulmonary tumour 
formation after intravenous injection of HCT 116 cells was 
significantly lower (P<0.025) in amiloride-treated mice, suggesting 
that receptor-bound uPA-initiated proteolysis was indeed required 
for colon cancer cells to arrest and grow in the lung interstitum. No 
matter which route of administration, amiloride produced similar 
decreased incidences of pulmonary metastasis formation 
suggesting that if the cancer cells could not pass through the 
pulmonary basement membrane within the first few hours post 1.v. 
injection, their metastatic potential was lost. Confirming the report 
of Morikawa et al., 1988, the incidence of pulmonary metastasis 
was much lower using KM 12SM cells (1 /6 mice) compared to 
HCT116 cells. 
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Table 5.4 Effect of amiloride . on the pulmonary tumour 
formation after intravenous injection of 
HCT116 cells 
Pulmonary Extrapulmonary 
Cells Amiloride metastasesa metastasesb 
HCT116 none 5/6 3/6 
HCT116 orall~ 116# 116 
HCT116 I-V 1f6# 116 
HCT116 1-V + or all~ 1f6# 116 
KM12SM none 1f6# 3/6 
a 
b 
# 
Number of positive mice I number of mice injected with human colon 
cancer cells; the mice were killed 42 days after intravenous injection 
of cancer cells. 
Mediastinal lymph node, renal lymph node. 
P < 0.025 compared to untreated HCT116 by Chi2-test 
5. 3. 4 Effect of blocking uPAR expression on the 
potential of HCT116 cells to form pulmonary 
tumour in nude mice after intravenous injection 
The effect of blocking uPAR expression on the metastatic 
potential of HCT116 cells was studied in the "intravenous" model. 
As shown in Table 5.5, macroscopic pulmonary metastases were 
found (and confirmed by histological examination) in I 0/16 mtce 
(62.5%) injected with untransfected HCT116 cells. Similar findings 
occurred In the mice inoculated with the sham-transfected 
subclone XTO (ie: with empty plasmid pXT 1 ), where 8/16 
presented with visible lung tumours and a further 2/16 mtce 
presented with microscopic metastases. In total, 62.5% of mtce 
injected with sham-transfected subclone XTO were affected .. In 
mice injected with HCT 116 cells transfected with an antisense 
uPAR eDNA fragment (clone XTll' 17), macroscopic pulmonary 
metastases were observed in only 1/16 mice, while microscopic 
metastases were found in a further 2116 mice. In total, 18.8% of 
mice injected with injected with uPAR antisense transfected clone 
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Table 5.5 Effect of blocking on 1 
form pulmonary s 
No. of p sesa 
CeHs mice macro- tumour metastases* 
HCT116 1 6 10/16 
XTO 1 6 8116 0-8 
XT11'17 1 6 1/16 
a. Number of positive mice I number of inoculated mice; the mice were killed 42 after intravenous of 
the cancer cells. b. P > 0.05 compared to untreated HCTl 6 -test. c. P < 0.05 compared to untreated HCT 16 
Chi2-test. *Mediastinal lymph nodes (9/16 in HCT116, 7/16 in 4/16 in XT11'17), renal 6 
HCT116, 4/16 in XTO, 0/16 in XT11'17) and cord (3/16 in HCT116, 1/16, in 0/16 in XT11'17) # 
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5.4 Discussion: 
In this chapter, the metastatic potential of the colon cancer 
cell lines, HCT 116 and KM 12SM wa-s compared using different 
implantation models. The data generated from the intravenous 
injection model are in agreement with the findings shown in the 
previOus chapters of this thesis. Taken together these findings 
strongly suggest that receptor-bound uPA-initiated proteolysis is 
important for colon cancer cells to invade host tissues and to 
penetrate blood vessels and disseminate via the circulation. Cell-
bound uP A activity in colon cancer cells injected into the 
circulation of mouse is also important in allowing cancer cells to 
cross the pulmonary basement membrane and implant into the 
pulmonary interstitum. 
Although HCT 116 and KM 12SM cells are quite different in 
terms of the relative numbers of cell surface uPA-binding sites, 
endogenous receptor-bound uPA activity and their potential to 
initiate plasminogen-dependant extracellular matrix degradation, 
there was no difference in metastatic behaviour between these 
two cell lines in the intrasplenic inoculation model. Possible 
explanations for these findings include: 
• receptor-bound uPA activity on KM12SM cell surface is high 
enough to initiate the process of plasminogen activation 
dependent pericellular proteolysis 
• KM12SM cells initiate the . . mvastve process by utilising 
proteinases other than uPA (eg: metalloproteinases, cathepsins, 
elastases) or 
• proteolysis is not required for colon cancer cells to implant into 
the liver when they have been injected into the spleen. 
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To explore these possibilities a variety of uPA and plasmin 
inhibitors wo,.:;, employed, based upon the logic that if plasmin is 
responsible for the pericellular proteolysis essential for colon 
cancer cells to implant into the liver following intrasplenic 
injection, inhibition of receptor-bound uPA activity or inhibition of 
plasmin activity should influence the hepatic implantation of 
cancer cells. Conversely, if uP A-driven pericellular proteolysis is 
not required for the process, uPA and plasmin inhibitors should 
have no effect. 
Table 5.3 shows that administration of amiloride, GGA-CMK or 
TrasylolR had no inhibitory effect on the development of 
experimental hepatic metastasis after intrasp1enic injection of 
HCT 116 or KM 12SM cells, despite the use of different methods of 
administration or a range of dosage levels. The amount of 
TrasyloiR injected into each mouse (10,000 KID/mouse/day) was 
20-fold higher than that used in the in vitro studies which 
resulted in complete inhibition of ECM degradation by HCT 116 cells 
in the presence of plasminogen. 
These results suggest that the uPA/p1asmin system may not 
be required for the intrasplenically-injected cancer cells to implant 
m the liver after spreading to that site. This may be due to the 
absence of basement membrane beneath the endothelial cells of 
the liver sinusoid [Bloom and Fawcett, 1975]. It has been reported 
that a few minutes after intrasplenic injection, 60% of HT29 cells (a 
colon cancer cell line) were found in the liver [Giavazzi et al., 
1986a]. In contrast, in the "intravenous" model of metastasis, the 
uPA/plasmin system may be required simply because basement 
membrane(s) are present beneath the vascular endothelial cell 
lining in the lung [Bloom and Fawcett, 1975]. In agreement with 
the data of Kellen et al. ( 1988) who examined experimental 
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pulmonary metastasis of a rat mammary adenocarcinoma, 
experimental pulmonary metastasis was significantly reduced by 
administration of amiloride and when uPAR expression was 
partially blocked using uP AR antisense transfection. 
The data reported here show that when uP AR-antisense 
transfected HCT 116 cells are given intravenously in the a thymic 
mouse model, the number of mice affected by pulmonary 
metastases is greatly reduced thereby implicating uPA in the 
invasion process. Earlier experiments however, that were 
performed before the antisense-transfected cells became available, 
used treatment with GGA-CMK, TrasyloiR and amiloride to reduce 
either uPA or plasmin activity. In these experiments which 
involved the intrasplenic route for producing hepatic metastases, 
there was no evidence to suggest that uPA was involved in the 
invasion process. It will be important therefore, administer uPAR-
antisense-transfected HCT 116 cells by the intrasplenic and 
intracaecal routes to determine whether the failure to show that 
inhibition of uPA or plasmin affects hepatic metastases is because 
uPA is not essential to the process itself or whether the means for 
depleting uPA or plasmin activity were ineffective. The results also 
raise the question as to whether the absence of a basement 
membrane m the liver contributes to the observed differeces in 
the occurence of metastases. 
An encouraging result In the prevention of experimental 
prostate adenocarcinoma metastases has been obtained by 
blocking cancer cell surface uPAR-bound activity using an inactive 
mutant uP A [Crowley et al., 1993]. These findings suggest that both 
uP AR and receptor- bound uP A may be potential therapeutic 
targets for the prevention of cancer invasion and metastasis. The 
data presented here suggest that the effect of uPA inhibitors on 
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the development of metastasis may be more efficient m particular 
cancers (eg: breast cancer) where the lungs are a major target 
organ of haematogenous metastasis. 
5. 5 Summary: 
In summary, the requirement for receptor- bound uP A in the 
process of colon cancer metastasis was examined in this chapter by 
companng the metastatic potential of HCT116 and KM12SM cells 
on several in vivo metastasis models, by utilising uPA and plasmin 
inhibitors in these models and by comparing the metastatic 
potential of uPAR antisense-transfected HCT 116 cells usmg an 
intravenous injection model. 
It was found that the metastatic potential of HCT 116 and 
KM12SM cells in the intracaecal implantation and the intravenous 
injection models was in agreement with their in vitro behaviour, 
but their metastatic potential in the intrasplenic implantation 
model was not. The experimental pulmonary metastases of HCT 116 
cells introduced intravenously was significantly inhibited by 
administration of amiloride, but the experimental hepatic 
metastases of HCT 116 cells or KM 12SM cells introduced 
intrasplenically was inhibited neither by amiloride and GGA-CMK 
nor by TrasyloiR. The potential of HCT 116 cells to form pulmonary 
metastases after intravenous injection was significantly reduced 
when the uPAR antisense-transfected clone, XT 11' 17 was used. 
These results indicate that in colon cancer, receptor-bound 
uPA-initiated proteolysis is required at the early steps of the 
metastatic process. Therefore, uPA inhibitors (eg: amiloride, GGA-
CMK and PAI-2) may have therapeutic potential in the prevention 
of colon cancer metastasis by inhibiting receptor-bound uPA-
mediated local tumour invasion and intravasation but cancer 
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cells have already escaped into the portal system may have 
reduced effectiveness. 
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CHAPTER 6 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
6.1 General Discussion 
6.1.1 Is uPAR-bound uPA activity essential to colon 
cancer invasion ? 
The in vitro investigations described m this thesis 
demonstrate that receptor-bound cell surface uPA is essential for 
colon cancer invasion through the initiation of a plasminogen-
dependent pericellular proteolytic cascade. This cascade generates 
plasmin on the surface of colon cancer cells which allows them to 
invade surrounding extracellular tissues including those associated 
with blood and lymphatic vessels. This conclusion is drawn from 
the following findings of this study: 
• the ability of colon cancer cells to activate plasminogen to 
plasmin depended on receptor-bound endogenous uPA 
activity 
• ECM degradation by intact colon cancer cells (HCT 116 or 
KM 12SM) correlated with receptor-bound endogenous uP A 
activity 
• ECM degradation by HCT 116 cells was reduced either by 
blocking the expression of uPAR gene or by inhibiting receptor-
bound uPA activity directly with uPA-specific inhibitors. 
The findings of this thesis are in strong agreement with those 
reported by Hollas et al. ( 1991 ), Cohen et al. ( 1991) and Ossowski 
et al. (1991) using the cell lines HCT 116, PC3 or HEp3 respectively 
that receptor-bound uPA, not soluble uPA is the main initiator of 
ECM degradation by these cancer cells and binding of uPA to uPAR 
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on the surfaces of cancer cells is critical for these cancer cells to 
degrade the ECM or to invade the MatrigelR in vitro. 
Since some components of the ECM (eg: types IV and V 
collagens) are not substrates directly degraded by plasmin, the cell 
surface plasminogen activation system may be not sufficient for all 
cancer cell types to degrade ECM components sufficiently to allow 
transit across these barriers. Many studies have suggested that 
other proteinases (eg: type IV collagenases) may also be intimately 
involved in the degradation of ECM macromolecular components 
preceding invasion and metastasis [Liotta 1986a,b; Liotta and 
Stetler-Stevenson, 1991 ]. Ossowski (1992) reported that all 
invasive human squamous carcinoma cell lines expressed high 
levels receptor-bound uP A activity. In the chorioallantoic 
membrane model, however, some of the squamous carcinoma cell 
lines expressing receptor-bound uPA activity alone were not 
invasive. In the invasive cell lines, a low molecular weight 
interstitial collagenase in addition to surface-bound uP A, was 
required for invasion of the chorioallantoic membrane. Yagel et a!. 
(1989) reported that amnion penetration by all invasive tumour 
cell lines could be completely abrogated by the addition of 
collagenase inhibitors. By contrast, inhibitors of plasmin and 
plasminogen activator reduced invasiveness in most, but not all 
cases. 
Human colon adenocarcinomas express uPAR m both the 
malignant cancer cells and resident macrophages located at 
invasive foci [Pyke et al., 1991 a], uP A [Pyke et al., 1991 a; 
Grondahl-Hansen et al., 1991], interstitial collagenase, the tissue 
inhibitor of metalloproteinases [Hewitt et al., 1991] and a Mr 72 kD 
type IV collagenase [Pyke et al., 1993] are produced and expressed 
m adjacent fibroblast-like stromal cells. In addition, a Mr 92 kD 
165 
type IV collagenase is found in macrophages [Pyke et al., 1993], 
while PAI-l is located in nearby endothelial cells in the tumour 
stroma [Pyke et al., 1991 b]. Taken together, these findings suggest 
that the uPA/plasmin system and the collagenases may operate in 
a concerted fashion during invasion and that the proteolytic 
activity is generated and controlled by the action of several cell 
types including malignant cells and cells resident in the stroma. 
Thses studies indicate that uPA-driven plasminogen activation 
is not the sole initiator of cancer cell pericellular ECM proteolysis. 
It IS thettore unlikely a single biochemical system is responsible 
for invasion and metastases by all tumour cell types. 
6.1.2 What is the role of receptor- bound uP A in the 
process of colon cancer metastasis ? 
As discussed In Chapter I, during tumour metastasis 
pericellular proteolysis may be required at several steps including 
those that encompass local invasion, intravasation, and 
extravasation. Local tumour invasion has been halted either by 
treatment with anti-human uP A antibodies [Ossowski et al., 1991] 
or by inducing overexpression of PAI-2 [Laug et al., 1993] (in 
human HEp3 squamous carcinoma and HT1080 fibrosarcoma cells 
respectively). In addition, 3T3 cells co-transfected with H-ras and 
human uP A genes colonised lungs more efficiently [Axelrod et al., 
1989], while expression of a mutant inactive uPA in PC3 cells led 
to suppression of spontaneous metastasis in vivo, through 
competitive displacement of active uPA from uPAR by the mutant 
enzymatically inactive uPA. These findings strongly suggest that 
receptor-bound uPA activity may be required at several steps in 
the metastatic process of these tumours. 
166 
In human colon cancer, in vitro studies [Baker et al., 1990; 
Cohen et al., 1991; Hollas et al., 1991] and clinical investigations 
suggest that receptor-bound uPA plays an important role in colon 
cancer metastasis. For example, there is a significant correlation 
between the Duke's histological staging of colon cancer 
invasiveness and the levels of pro-uPA antigen found m the 
tumour [Sim et al., 1988]. Urokinase antigen was localised to the 
"invading front" using immunoperoxidase staining [Kohga et al., 
1985] and using in situ hybridization technology, uP A mRN A 1s 
expressed in tumour-associated stromal cells while uP AR mRN A IS 
localised to malignant colonic epithelial cells in the areas of cancer 
invasion [Pyke et al., 199la]. 
To the best of my knowledge, the studies represented here are 
the first in vivo experimental investigations concerning the role of 
receptor- bound uP A m the process of human colon cancer 
metastasis. Human colon cancer cells were introduced into the 
athymic nude mice at different sites, and the pattern of the 
metastasis resulted was dependent upon the site of implantation, 
as has previously been observed [Giavazzi et al., 1986; Morikawa 
et al., 1988]. After intracaecal implantation, human colon cancer 
cells grew at the implantation site and spread to the mesenteric 
lymph nodes and the liver. Although the incidence of hepatic 
metastasis post-intracaecal inoculation in this study was lower 
than that reported by Morikawa et al. (1988), our data correlates 
with the uPA activity bound on the surfaces of these cells and with 
the ability of these cells to degrade ECM in the presence of 
plasminogen. The incidence of hepatic tumour formation after 
intrasplenic injection was consistently high ( -90% In each 
experiment). Conversely, the potential to form hepatic tumours 
after intrasplenic inoculation did not correlate with receptor-
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bound uPA activity nor with their ability to degrade ECM. In 
agreement, hepatic metastasis was not altered by inhibiting 
receptor-bound uPA activity using specific inhibitors (eg: amiloride 
& GGA-CMK) or by inhibiting plasmin activity (eg: Trasylol) 
generated on the cell surface. By contrast, pulmonary tumour 
formation after intravenous injection correlated strongly with 
receptor-bound uPA activity and their potential to mediate 
plasminogen-dependent ECM degradation. Supporting this 
contention, formation of pulmonary metastases after intravenous 
injection was substantially reduced either by inhibiting receptor-
bound uPA activity or by partially blocking uPAR gene expression. 
Putting these data together, it would appear that receptor-
bound uPA is necessary in the early steps of the process of colon 
cancer metastasis, especially those that facilitate local invasion and 
intravasation,. Conversely, uPAR-bound uP A may be not required 
for colon cancer cells to implant into and grow in the liver once the 
malignant cells have entered the portal system [Bloom and 
Fawcett, 1975]. 
6.1.3 Do receptor-bound uPA and uPAR 
potential targets for antimetastatic 
represent 
therapy ? 
Tumour metastasis is an inefficient process. A tumour cell 
must successfully complete a number of crucial, sequential steps 
before a metastasis is established [Weiss 1990]. This scheme of 
events implies that the inhibition of any one of these steps might 
lead to a reduction in the incidence of metastasis. 
Since receptor-bound uPA-initiated pericellular proteolysis is 
required for many types of tumour cells to invade, plasminogen 
activation on tumour cell surfaces is more efficient than that in 
solution and uPA binds to specific overexpressed tumour cell 
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receptors (uPAR), this would appear to be an appropriate point at 
which to contemplate therapeutic intervention. It is distinctly 
possible to inhibit the migration and spread of tumour cells by 
decreasing production of uP A or uP AR, preventing the interaction 
of uPA with uPAR or by inhibiting receptor-bound uPA activity 
directly [Fazioli and Blasi, 1994]. 
The interaction of uP A with tumour cell surface uP AR can be 
interfered by competitive displacement of active uPA with inactive 
ligands (eg: chemically modified or recombinant inactive mutant 
uPA) [Crowley et al., 1993], or by competing for binding sites with 
a soluble ligand-binding uP AR [Masucci et al., 1991]. In addition, 
receptor-bound uPA activity on tumour cell surfaces can be 
inhibited by monoclonal antibodies [Ossowski et al., 1991], by 
PAis(eg: PAI-l or PAI-2) [Ellis et al., 1990; Cajot et al., 1990; Baker 
et al., 1990], or by specific chemical inhibitors such as amiloride 
and recently described amiloride derivatives [Vassalli and Belin, 
1987; Towle et a!., 1993]. 
The studies represented here indicate that: 
• uPA inhibitors such as PAI-2, amiloride and GGA-CMK are 
effective in -stopping colon cancer invasion by inhibiting 
plasminogen-dependent ECM degradation 
• anti-metastatic therapies using receptor-bound uPA or uPAR as 
the target (s) may be more efficient in tumours such as 
breast cancer in which the lungs are the preferential organ for 
metastases formation 
• uPA inhibitors may prove to be excellent inhibitors of local 
invasion and extravasation. 
It may also be necessary to consider mechanisms which are 
independent of endogenous tumour proteases since in a nude mice 
model of human squamous carcinoma, local invasion of the 
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subcutaneous tumour was inhibited usmg human uPA antibodies 
while distant metastases formation was not [Ossowski et al., 1991]. 
One possible mechanism suggested by Ossowski et al., ( 1991) was 
that granulocytes infiltrating into the tumour assist tumour cells in 
breaching some biological barriers. Another possible inhibitory 
mechanism worth considering is that the intravasation step may 
be facilitated by the process of angiogenesis where newly formed 
vessels in the tumour are fragile and highly permeable due to an 
immature basement membrane [Blood and Zetter, 1990] and that 
stopping angiogenesis with uPA-inhibitors may also result in 
inhibition of intravasation. 
6.2 Future Directions 
6.2.1 To confirm the role of receptor-bound uPA in the 
process of colon cancer metastasis 
Although the findings represented here the role of 
receptor-bound uPA in the process of colon cancer invasion and 
strongly suggest its important role in the process of colon cancer 
metastasis, further investigations are still required. 
In human colon cancer, the mesenteric lymph nodes and liver 
(not the lungs) are the preferential targets of metastasis. 
Unfortunately, the effects of inhibition of receptor-bound uP A or 
blocking uPAR gene expression on human colon cancer metastasis 
m nude mice have not been examined m the intracaecal 
implantation model because of the low incidence of metastases in 
this model. Despite this micrometas~~ may have been present but 
histologically "silent". Because of these observations, there is an 
urgent need to improve the early detection of micrometastasis m 
animal models. A recent means of overcoming this problem 
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[Crowley et al., 1993] involves transfecting PC3 cells with a 
plasmid encoding the chloramphenical acetyltransferase (CAT) 
gene which is subsequently employed as a sensitive detection 
r. 
maker of spontaneous metastasis of the human prostate 
adenocarcinoma PC3 in nude mice. Instead of employing routine 
histological examination, CAT activity in the organs proved to be a 
very sensitive means of detecting micrometastases that will be 
detectable as few as 250 tumour cells in mouse organs except 
the liver, because CAT is degraded in the liver. Therefore, this 
strategy may be useful for . . 1mprovmg the "spontaneous" 
intracaecal metastasis model of colon cancer in nude mice. Instetzd 
-ti1e. 
of,CAT gene, luciferase gene or other reporter genes will be used. 
Colon cancer cells such as HCT 116 cells will be transfected with a 
plasmid encoding luciferase gene and luciferase-expressing 
subclones selected and implanted into the mouse caecum allowing 
detection of micrometastases by measuring the activity of 
luciferase in mouse organs such as the mesenteric lymph node and 
the liver [Alam and Cook, 1990; Zhang et al., 1994]. 
To completely exclude any role for receptor-bound uPA in the 
process of colon cancer cell implantation into the liver, cell lines 
that were "null" uPAR, "null" uPA or both should be produced. In 
order to establish these lines, different uPAR antisense plasmid 
constructs including the promoter regions, start codon or full-
length uPAR mRNA could be constructed to generate cell lines in 
which the expression of uP AR was completely blocked. 
6.2.2 To determine the role of endogenous PAI-l m the 
process of colon cancer invasion and metastasis 
Generally, tumour invasion and metastasis may be the result 
of an imbalance of positive and negative regulation, the negative 
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factors may be just as important as positive elements [Liotta and 
Stetler-Stevenson, 1991]. Induction of a recombinant protein, 
tissue inhibitor of metalloproteinase 2 (TIMP-2), in tumorigenic, 
invasive and metastatic rat cells completely suppressed local tissue 
invasion and partially suppressed hematogenous metastasis 
[DeClerck et al., 1992]. In another report, the local invasion of 
human sarcoma cells, (HT 1 080) in nude mice after subcutaneous 
injection was significantly inhibited by inducing the expression of 
recombinant PAI-2 in these cells [Laug et al., 1993]. 
Some preliminary experiments have been conducted 
concernmg endogenous PAI-l and PAI-2. In tissue culture, HCT116 
cells express both PAI-l mRNA and protein but not PAI-2 mRNA 
or protein. Addition of PAI-l antibody to the culture of HCT 116 
cells resulted m increased receptor- bound endogenous uP A 
activity (data not shown). These results are m agreement with the 
findings reported [Stephens et al., 1989; Paul et al., 1990; Cohen e t 
al., 1991]. PAI-l IS one of the physiological inhibitors of uPA and it 
can inhibit both soluble and receptor-bound uP A [Ellis et al., 1990] 
and ECM degradation by colon cancer cells [Cajot et al., 1990]. Since, 
P AI -1 antigen levels correlate with worse prognosis in breast 
cancer [Janicke et al., 1991], it is clear that there are many more 
studies which need to be carried out before the role of endogenous 
PAI-l in the colon cancer invasion and metastasis is characterised. 
6.2.3 Polarity for therapy in colon-rectal carcinoma 
based on findings in this thesis and reports in 
literature 
Receptor-bound uPA Is involved in the mvastve process of 
colo-rectal cancer. The relevance of this finding to future 
developments in management of established colo-rectal cancer 
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depends on the confirmation of the role of cell surface uP A and 
the 
uPAR by in vivo experiments on Nu/Nu mouse model as described 
in Chapter 5. 
With receptor-bound uPA and uPAR as the targets, there are a 
number of potential candidate therapies. These are: 
• introducing uPAR antisense oligodeoxynucleotides [Rothenberg 
et al., 1989] to block the expression of uPAR on the surfaces of 
cancer cells using selective arterial injection, 
-fl 
• using inactive ligands to block unoccupied uPAR or as competive 
antagonists to active uPA (55kDa) [Crowley et al., 1993], 
• administration of uPA inhibitors (such as PAI-2, or amiloride) to 
inhibit the receptor-bound uP A activity directly, 
• targetting cancer cell surface uPARs with uPA-toxin conjugates 
such as uPA-saporin conjugate which is selectively cytotoxic to 
uPAR-expressing cells. 
One of the maJor problems of developing new therapies usmg 
above approaches, is the serious potential of side-effects, because 
many normal cell types such as monocytes and neutrophiles, also 
express uPAR under physiological conditions. New molecules that 
selectively inhibit uPA or uPAR on the surfaces of cancer cells, but 
not on normal cells, represent an important future prospect for 
cancer therapy. 
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